



Royal Brisbane and Women's Hospital

RBWH Research Report 2025

Cancer Care Services

Metro North
Health



Queensland
Government



Metro North Health acknowledges the Traditional Custodians of the Land upon which we live, work and walk, and pay our respects to Elders both past and present.

Published by the State of Queensland (Metro North Hospital and Health Service), June 2026



This document is licensed under a Creative Commons Attribution 3.0 Australia licence.

To view a copy of this licence, visit creativecommons.org/licenses/by/3.0/au

© State of Queensland (Metro North Hospital and Health Service) 2026

You are free to copy, communicate and adapt the work, as long as you attribute the State of Queensland (Metro North Hospital and Health Service).

For more information, contact:

RBWH Research Services, Metro North Hospital and Health Service, Level 8, Block 7, Herston QLD 4029, email RBWH_Research_ESO@health.qld.gov.au

An electronic version of this document is available at <https://metronorth.health.qld.gov.au/rbwh/research>

Disclaimer:

The content presented in this publication is distributed by the Queensland Government as an information source only. The State of Queensland makes no statements, representations or warranties about the accuracy, completeness or reliability of any information contained in this publication. The State of Queensland disclaims all responsibility and all liability (including without limitation for liability in negligence) for all expenses, losses, damages and costs you might incur as a result of the information being inaccurate or incomplete in any way, and for any reason reliance was placed on such information.

Contents

Cancer Care Services 4

Haematology/BMT 5

Haemophilia Centre..... 6

Radiation Oncology 20

Medical Oncology 31

Cancer Care Nursing Research 60

Allied Health Professions 67

Cancer Care Services



Associate Professor Melissa Eastgate
Executive Director
Cancer Care Services

In 2025, Cancer Care Services at the Royal Brisbane and Women's Hospital delivered one of its strongest research years to date, with major achievements across Allied Health, Cancer Nursing, Haematology & BMT, Medical Oncology, Radiation Oncology and the Queensland Haemophilia Centre.

Cancer Nursing made substantial progress aligned with its 2024–2027 Research Action Plan. A prestigious \$984,737 MRFF grant was received to improve the uptake of clinical genomics across Queensland Cancer Services. Additional grants totalling >\$150,000, including RBWH Project Grants, the Carla Patterson Memorial Grant, and fellowship/scholarship funding were also won.

The Haematology/BMT program advanced clinical innovation across stem cell transplantation, cellular therapy, microbiome science, and genomics. They have contributed to significant advances in GVHD prevention, immune reconstitution, and microbiome-modifying interventions. There has also been expansion of CAR-T and novel immunotherapy trials in lymphoma and myeloma. The team have more than \$11 million in active grants, including NHMRC, MRFF, ACRF and Cancer Australia funding.

The Queensland Haemophilia Centre continued to play a national leadership role in inherited bleeding disorder research including participation in an international Phase 1/2 trial for severe von Willebrand disease: Phase 3 commencing in 2026.

Medical Oncology delivered an exceptionally productive year across clinical trials, academic output, and national leadership. The team launched several new trials, with significant collaborations with QIMR Berghofer Medical Research Institute, the Department of Nuclear Medicine and the Herston Imaging Research Facility. The department contribute to more than 30 peer-reviewed publications, including in *NEJM*, *The Lancet*, *JCO* and *EJC*. Two RBWH studies (CHALLENGE, DESQUAMATE) were presented at ASCO 2025 (American Society of Clinical Oncology annual meeting). Dr Zarnie Lwin was awarded the title of Professor (UQ).

Radiation Oncology is a technology driven specialty, with a focus on improving new techniques and technology to improve patient outcomes and reduce toxicity. The department had 2 staff complete PhDs and Professor Lizbeth Kenny AO was awarded the Metro North Chief Executives award for her significant contributions to cancer care during her career.

Our clinical trials team completed a significant restructure with the aim of harmonising processes, providing access to career progression and career development and position the unit for the future. The newly created I-CARE Clinical Trials Team received the 2025 Metro North Research Support Award, a well-deserved recognition of the vital role they play in Cancer Care Research.

Allied Health strengthened its translational, patient-centred cancer research program across speech pathology, dietetics, and multidisciplinary teams. Key achievements included researcher that produced international evidence-based frameworks for swallow assessment following laryngectomy. More than \$250,000 was awarded to Dr Sarah Anderson's team for research into prebiotic fibre supplementation during allogeneic stem cell transplantation.

Overall Impact

In 2025, Cancer Care Services secured significant national research funding, expanded clinical trial opportunities for patients, strengthened its research workforce, and led innovations across genomics, cellular therapy, supportive care, microbiome science, and gene therapy. This integrated research effort continues to position RBWH as a national leader in cancer research and high-value clinical translation.

Haematology/BMT



Dr Cameron Curley
Director Clinical Haematology & BMT

In 2025, the Haematology/BMT research program continued to deliver clinically impactful advances across stem cell transplantation, cellular therapies, precision haemato-oncology and benign haematology. Our research remains embedded in clinical care, ensuring RBWH patients have access to innovative therapies, improved supportive care strategies and molecularly informed treatment pathways.

Transplant-focused studies advanced graft-versus-host disease prevention, immune reconstitution and microbiome-directed interventions, reducing infectious complications and improving post-transplant recovery. Cellular therapy activity expanded through CAR-T and novel immunotherapy trials in lymphoma and myeloma, strengthening local capability in toxicity mitigation and long-term outcome monitoring. Precision medicine initiatives, including genomic profiling and platform trial participation, enabled targeted approaches for high-risk haematological malignancies. In benign haematology, gene therapy trials for haemophilia A and B continued to reduce treatment burden and improve long-term disease control.

Grants awarded / active in 2025 (major funding):

- **NHMRC Ideas Grant** – *Harnessing the Gut Microbiome to Improve Stem Cell Transplant Outcome* – **\$1,720K** (2024–2027)
- **MRFF Global Health Grant** – *Unlocking the Gut Microbiome to Track the Spread of AMR Genes and Pathogens* – **\$1,991K** (2023–2027)
- **NHMRC Investigator Grant (L1)** – *Translation of Genetic Findings to Improve Outcomes for Patients with Blood Cancers* – **\$1,913K** (2021–2025)
- **MRFF Clinical Trials Activity Grant** – *MoST-LLy Molecular Screening and Therapeutics Program* – **\$2,689K** (2021–2025)
- **Australian Cancer Research Foundation (ACRF)** – *Centre for Optimised Cancer Therapy* – **\$2,000K** (2023–2028)
- **Genomics Health Futures Fund (MRFF)** – **\$985K** (2024–2029)
- **Cancer Australia Grant** – *Partnerships for Culturally Safe Cancer Care* – **\$957K** (2024–2027)
- **RBWH Foundation Grant** – *FAPI PET Pulmonary GVHD Study* – **\$25–50K**
- **RBWH SERTA Research Project Grant** – *FDG-PET in Gastrointestinal GVHD* – **\$25–50K**

Haemophilia Centre



Dr Jane Mason
Director of Queensland Haemophilia Centre

2025 was another exciting year for the Queensland Haemophilia Centre (QHC) working in collaboration with the Clinical Research Unit Cancer Care Services and the Cellular Therapy / BMT Laboratory. In the Von Willebrand space, the QHC were involved in an international study exploring treatment options for severe von Willebrand disease, which included recruitment of phase 1/2 patients. We are continuing onto phase 3 for this same product in 2026. We continued to demonstrate excellence in the gene therapy space, playing a pivotal role in a phase 3 haemophilia B gene therapy study investigating whether men with pre-existing antibodies against the AAV vector still demonstrate reasonable response. Dr Campbell, in her role as Clinical Research Consultant for the Australian Haemophilia Centre Directors Organisation (AHCDO), organised and chaired the annual education day, where novel investigator-initiated work from our centre around stability of long-acting factor VIII concentrates and emicizumab was presented. We are also commencing a phase 1 gene therapy trial in Haemophilia B using CRISPR/Cas9 in addition to AAV vector technology.

Research Awards and Achievements

Recipient (RBWH staff in bold)	Award	Event
Integrated Cancer Research (I-CARE) Collaborative – Clinical Trials	Research Support Award	Metro North Health (2025 Research Excellence Awards)

Research Grants

Investigator Names (RBWH staff in bold)	RBWH Departments / Research Groups	Research Project Title	Granting Body	Total Awarded (whole all years)	Length of Awards in years and years active
Dr Andrea Henden	Haematology/BMT Cancer Care Services	A Centre of Research Excellence in Supportive Care for People with Blood Cancers	NHMRC (National Health and Medical Research Council)	\$3,000,000	01/01/2026–31/12/2031
Ross Lindell-Innes (CI-A) and Ashleigh Scott (CI-B)	Haematology/BMT Cancer Care Services	323 - 68GA FAPI PET Assessment of Pulmonary Chronic Graft Versus Host Disease	2025 RBWH Foundation Grant	\$25,000 - \$50,000	1 year 1/01/25 – 1/01/26
Dr Ashleigh Scott	Haematology/BMT Cancer Care Services	RBWH-PG-018-2025 - FDG-PET prediction of gastrointestinal graft-versus-host disease	2025 RBWH Research Project Grants - SERTA	\$25,000 - \$50,000	2 years 1/1/25-31/12/2026

Investigator Names (RBWH staff in bold)	RBWH Departments / Research Groups	Research Project Title	Granting Body	Total Awarded (whole all years)	Length of Awards in years and years active
Dr Ashleigh Scott	Haematology/BMT Cancer Care Services	Implementing molecular imaging and microbial biomarkers to deliver precision medicine in cancer immunotherapy	MNHHS Clinician Research Fellowship	0.4 FTE	2024-2027
Dr Ashleigh Scott	Haematology/BMT Cancer Care Services	Harnessing the gut microbiome to improve stem cell transplant outcome	NHMRC Ideas Grant (CI-D)	\$1,719,764	2024-2027
Associate Professor Andrea Henden	Haematology/BMT Cancer Care Services	Unlocking the gut microbiome to track the spread of AMR genes and pathogens	2023 MRFF Global Health Grant	\$1,990,643	2023-2027
Professor Steven Lane	Haematology/BMT Cancer Care Services	Translation of genetic findings to improve outcomes for patients with blood cancers.	NHMRC Investigator Grant, L1.	\$1,913,403	2021-2025
Professor Steven Lane	Haematology/BMT Cancer Care Services	Rare Cancers and Unmet Need: MoST-LLy, Molecular Screening and Therapeutics Leukaemia and Lymphoma	MRFF Clinical Trials Activity	\$2,688,736	2021-2025
Professor Steven Lane, Associate Professor Siok Tey, Glen Kennedy, Andrea Henden	Haematology/BMT Cancer Care Services / QIMRB	ACRF Centre for Optimised Cancer Therapy	Australian Cancer Research Foundation - ACRF	\$2,000,000	2023-2028
AI: Glen Kennedy	Haematology/BMT Cancer Care Services	Genomics Health Futures Fund	Medical Research Future Fund (MRFF)	\$984,738	2024-2029
PI: G Kennedy/M Eastgate	Haematology/BMT Cancer Care Services	Partnerships for culturally safe cancer care	Cancer Australia	\$956,516	2024 - 2027

RBWH Department / Research Group Led Research Activity

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
Andrea Henden	Ashleigh Scott, Caroline McNamara, Glen Kennedy, Kirk Morris, Siok Tey, Stewart Hunt;	T2MR - Performance of emerging microbiological techniques for the diagnosis of severe infections in neutropenic patients with haematological malignancies.	Involvement	9
Andrea Henden	Cameron Curley, Siok Tey, Elango Subramonia Pillai, Ashleigh Scott, Steven Lane, Glen Kennedy, Jason Butler, James Morton, Heshani Mediwake	"Micro GVHD" - Faecal Microbial Transplantation for Graft-Versus-Host Disease.	Involvement	1

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
Andrea Henden	Cameron Curley, Siok Tey, Elango Subramonia Pillai, Ashleigh Scott, Steven Lane, Cheryl Hutchins, Glen Kennedy, Jason Butler, Heshani Mediwake, Kirk Morris	CARTOS - Chimeric Antigen Receptor-T cell Observational Study.	Involvement	0
Andrea Henden	Cameron Curley, Siok Tey	COVEM - COVID-19 Vaccine Efficacy in patients with Haematological Malignancy.	Involvement	0
Andrea Henden	Glen Kennedy, Cameron Curley, Jason Butler, Elango Subramonia Pillai, Ashleigh Scott, Kirk Morris, Nicholas Weber, Caroline McNamara, Stewart Hunt, Nilu Perera, Siok Tey, Ross Lindell-Innes	KITE 0601 - A Phase 1 Open-label, Single Arm, Multicentre Study Evaluating the Safety and Efficacy of KITE-197 in Subjects with Relapsed or Refractory Large B-cell Lymphoma	Involvement	1
Andrea Henden	Cameron Curley, Caroline McNamara, Elango Subramonia Pillai, Glen Kennedy, Jason Butler, Kirk Morris, Nicholas Weber, Nilu Perera, Siok Tey, Stephen Boyle, Stewart Hunt, Ross Lindell-Jones	Janssen Mono CAR - A Phase 1b Multicentre, Open-Label, Study of JNJ-90009530, an Autologous Anti-CD20 CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (90009530LYM1001)	Involvement	0 ON HOLD
Andrea Henden/ Ashleigh Scott	Ashleigh Scott; Siok Tey; Glen Kennedy; Jason Butler; Nilu Perera; Nicholas Weber; Andrew Dow; Sean McKeague; Stewart Hunt; Elango Subramonia Pillai; Cameron Curley;	The Microbiome in Transplant and Cellular Therapy (Micro-TCT) **theranostics**	Involvement	11
Ashleigh Scott	Andrea Henden, Cameron Curley, Elango Subramonia Pillai, Glen Kennedy, Stewart Hunt, Ross Lindell-Innes, Jason Butler, Siok Tey, Ross Lindell-Jones	ANZHIT2 - A multi-centre phase II, Australian and New Zealand, exploratory study of amendments to conditioning regimens in haplo-identical stem cell transplantation	Involvement	5
Ashleigh Scott	Antiopi Varelias, Andrea Henden, Quan Nguyen, Glen Kennedy, Sunil Lakhani, Joshua Satchwell	Immune cell profiling using spatial transcriptomics in gastrointestinal graft versus host disease.	Involvement	0
Ashleigh Scott	Cameron Curley, Glen Kennedy, Siok Tey, Andrea Henden, Elango Subramonia Pillai, Jason Butler, Stewart Hunt, Ross Lindell-Jones	CYP-GVHD-P2-01 - Multicentre, Randomized, Double-blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of CYP-001 in Combination with Corticosteroids vs Corticosteroids Alone for the Treatment of High-Risk Acute Graft Versus Host Disease	Involvement	2

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
Caroline McNamara	Stewart Hunt, Steven Lane, Kirk Morris, Luani Barge, Ross Lindell-Innes, Michelle Spanevello, Cameron Curley, Nilu Perera, Ashleigh Scott, Nicholas Weber, Becky Leung	AMGEN Golden Gate - Phase 3 Randomized, Controlled Study of Blinatumomab Alternating with Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia With Safety Run-in	Involvement	1
Caroline McNamara	Steven Lane, Kirk Morris, Nicholas Weber, Ashleigh Scott, Cameron Curley	Geron IMPACT MYF3001 - A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK) Inhibitor	Involvement	0
Caroline McNamara	Steven Lane, Kirk Morris, Ashleigh Scott, Cameron Curley, Nilu Perera, Stewart Hunt, Elango Subramonia Pillai, Siok Tey, Andrea Henden	INCYTE INCA - A Phase 1, Open-Label, Multicenter Study of INCA033989 Administered as a Monotherapy or in Combination with Ruxolitinib in Participants With Myeloproliferative Neoplasms	Involvement	3
Glen Kennedy	Andrea Henden, Ashleigh Scott, Cameron Curley, Elango Subramonia Pillai, Jason Butler, Siok Tey	NKARTA - A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects with B-cell Malignancies	Involvement	0
Jane Mason	Sally Campbell	BioMarin BMN 270-303 GENE8-3: A Phase 3b, Single Arm, Open-Label Study to Evaluate the Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII, with Prophylactic Corticosteroids in Haemophilia A Patients	Involvement	0
Jane Mason	Sally Campbell, Nicholas Weber	CSL222_3005 IX-TEND - A Phase 3b, Open label, Multicentre, Single-dose Study Investigating Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy Administered to Adult Subjects with Severe or Moderately Severe Haemophilia B with Detectable Pretreatment AAV5 Neutralizing Antibodies	Involvement	2
Jane Mason	Sally Campbell	BioMarin BMN270-401 - A Long-Term Follow-Up Study in Subjects with Severe Haemophilia A Who Received BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in a Prior BioMarin Clinical Trial	Involvement	8

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
Jane Mason	Sally Campbell, Nicholas Weber, Antoinette Runge, Michelle Spanevello	Vega Therapeutics VGA039-CP001 VIVID-2 - A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of VGA039 Following Intravenous or Subcutaneous Administration of Single Ascending Doses in Healthy Adults and Adult Patients with von Willebrand Disease	Involvement	0
Jane Mason	Michelle Spanevello, Sally Campbell	Pfizer C0371002 - Phase 3, open label, multi-cohort, multi-centre study of FIX gene transfer with PF-06838435 (rAAV-Spark100-hFIX-Padua) in adult male participants with moderately severe to severe haemophilia B (FIX:C=2%) (BeneGene-2)	Involvement	0
Jason Butler	Andrea Henden, Siok Tey, Cameron Curley, Elango Subramonia Pillai, Ashleigh Scott, Stewart Hunt, Glen Kennedy	SANOFI EFC17757 ROCKnrol-1 - A randomized, double-blind, multicentre, Phase 3 study to evaluate efficacy and safety of belumosudil in combination with corticosteroids versus placebo in combination with corticosteroids in participants at least 12 years of age with newly diagnosed chronic graft versus host disease (cGVHD)	Involvement	0
Jason Butler	Cameron Curley, Glen Kennedy, Elango Subramonia Pillai, Siok Tey, Nicholas Weber, Kirk Morris, Ashleigh Scott	Novartis E2202 ELARA - A Phase II, single arm, multicentre open label trial to determine the efficacy and safety of tisagenlecleucel (CTL019) in adult patients with refractory or relapsed follicular lymphoma	Involvement	0
Jason Butler	Elango Subramonia Pillai, Kirk Morris	Novartis CCTL019A2205B – PAVO: Long term follow-up of patients exposed to Lentiviral-Based CD19 directed CAR T-Cell therapy	Involvement	1
Jason Butler	Cameron Curley, Simon Durrant, Kirk Morris, Elango Subramonia Pillai, Siok Tey, Nicholas Weber, Glen Kennedy	Acerta 308 ECHO – A Phase 3, Randomized, Double blind, Placebo controlled, Multicentre Study of BR alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell 3Lymphoma	Involvement	0
Jason Butler	Andrea Henden, Ashleigh Scott, Cameron Curley, Elango Subramonia Pillai, Glen Kennedy, Siok Tey, Ross Lindell-Jones	Janssen CARTITUDE 5 - A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy	Involvement	0

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
Jason Butler	Andrea Henden, Ashleigh Scott, Cameron Curley, Elango Subramonia Pillai, Glen Kennedy, Siok Tey, Ross Lindell-Jones	EMN 28 CARTITUDE 6 - A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucl versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in Participants with Newly Diagnosed Multiple Myeloma who are Transplant Eligible	Involvement	0
Jason Butler	Andrea Henden, Ashleigh Scott, Kirk Morris, Cameron Curley, Nicholas Weber, Nilu Perera, Elango Subramonia Pillai, Glen Kennedy, Siok Tey, Stewart Hunt	KITE ZUMA 23 - A Phase 1 Open-label, Single Arm, Multicenter Study Evaluating the Safety and Efficacy of KITE-197 in Subjects with Relapsed or Refractory Large B-cell Lymphoma	Involvement	3
Jason Butler	Cameron Curley;Elango Subramonia Pillai ;Kirk Morris; Nicholas Weber; Caroline McNamara; Andrea Henden; Ashleigh Scott; Nilu Perera; Stewart Hunt;Ross Lindell-Innes	AbbVie M22-003 EPCOR FL-2: A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2)	Involvement	0
Jason Butler	Jason Butler	NHMRC FL Prognostic - Integrating immunity and genetics in Follicular Lymphoma to establish a prognostic score fit for the modern era	Involvement	0
Kirk Morris	Kirk Morris	Watch and Wait FL - The role of surveillance imaging in patients undergoing a watch and wait approach in advanced stage follicular lymphoma.	Involvement	0
Nicholas Weber	Nilu Perera, Stewart Hunt, Kirk Morris, Jason Butler, Ross Lindell-Jones	REGENERON LINKER - Open-Label Randomized study to evaluate lincoseltamab versus EPd in Relapsed/Refractory Multiple Myeloma - RGN5458-ONC-2245 LINKER-MM3	Involvement	1
Nicholas Weber	Jason Butler, Ashish Misra, Kirk Morris, Cameron Curley, Elango Subramonia Pillai	Beigene 304 - An International, Phase 3, Open-label, Randomized Study of BGB 3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Involvement	0
Nicholas Weber	Jason Butler, Kirk Morris	DREAMM 7 - A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared with the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants with Relapsed/Refractory Multiple Myeloma	Involvement	0

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
Nicholas Weber	Kirk Morris, Jason Butler, Stewart Hunt, Nilu Perera, Ross Lindell-Innes, Becky Leung	DREAMM 10: Phase 3, Randomized, Open-Label Study of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone Versus Daratumumab, Lenalidomide, and Dexamethasone in Participants with Newly Diagnosed Multiple Myeloma who are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) - DREAMM-10	Involvement	0
Nicholas Weber	Kirk Morris, Jason Butler, Nilu Perera, Stewart Hunt, Ross Lindell-Innes, Becky Leung;	Pfizer C1071032 MAGNETISMM-32 : A Phase 3, Open-Label Study of Elranatamab Monotherapy Versus Elotuzumab, Pomalidomide, Dexamethasone (EPd) or Pomalidomide, Bortezomib, Dexamethasone (PVD) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed/Refractory Multiple Myeloma Who Received Prior Anti-CD38 Directed Therapy	Involvement	2
Sally Campbell	Jane Mason	Rare Factor Deficiencies & AT Knockdown - Evaluating the in vitro effect of antithrombin (AT) inhibition on thrombin generation in patients with severe Factor V, Factor VII or Factor XI deficiencies by AT-antibodies	Involvement	0
Siok Tey	Glen Kennedy, Cameron Curley, Jason Butler, Elango Subramonia-Pillai, Ashleigh Scott, James Morton	CSL Behring MODULAATE - A Phase 2/3, Multicentre, randomized, Double-blind, placebo-controlled, study to evaluate the safety and efficacy of Alpha-1 AntiTrypsin for the Prevention of graft-versushost disease in patients receiving hematopoietic cell transplant	Involvement	2
Siok Tey	Glen Kennedy, James Morton, Jason Butler, Elango Subramonia-Pillai, Cameron Curley	IL-17 – Observational study of IL-17-related cytokines in stem cell transplantation	Involvement	0 ON HOLD 2019
Siok Tey	Glen Kennedy, Cheryl Hutchins	TREG Apheresis - Developing a method to generate regulatory T cells from healthy donors	Involvement	0
Siok Tey	Siok Tey	IR Auto – Observational study of immune reconstitution in patients undergoing autologous stem cell transplantation	Involvement	0 ON HOLD 2019
Siok Tey	Siok Tey	IR Allo - Observational study of immune reconstitution following stem cell transplantation		

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
Siok Tey	Glen Kennedy James Morton, Jason Butler, Elango Subramonia-Pillai, Cameron Curley	HAPLO - A Phase I Study of Haploidentical Haematopoietic Stem Cell Transplantation with Add-Back of Donor T Cells Transduced with Inducible Caspase 9 Suicide Gene in Patients with Poor Risk Haematological Malignancies	Involvement	0
Siok Tey	Glen Kennedy, Cheryl Hutchins	CAR T cells in Healthy Volunteers: Generating Chimeric Antigen Receptor (CAR T) cells from healthy volunteers	Involvement	0
Siok Tey	Andrea Henden, Ashleigh Scott, Cameron Curley, Cheryl Hutchins, Elango Subramonia Pillai, Glen Kennedy, Heshani Mediwake, James Morton, Jason Butler, Kari Mudie;	CARTey1 Phase I Clinical Trial of MB. CART19.1 CD19 Chimeric Antigen Receptor (CAR) T Cells in Relapsed or Refractory CD19-Positive Haematological Malignancy	Involvement	4

Collaborative Research Activity Involving RBWH Department / Research Group

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
Andrea Henden PMCC	Siok Tey, Cameron Curley, Kirk Morris, Elango Subramonia Pillai, Nilu Perera, Stewart Hunt, Caroline McNamara, Nicholas Weber, Ross Lindell-Innes	(EpLCART) - A Phase II Open-Label, Multi-Centre Study of Minimal Residual Disease-Directed Consolidation with Epcoritamab or Epcoritamab-Lenalidomide-Rituximab Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma (EpLCART)	Involvement	2
Andrea Henden PMCC	Becky Leung, Jason Butler, Nicholas Weber, Caroline McNamara, Stewart Hunt, Nilu Perera, Ross Lindell-Innes, Elango Subramonia Pillai, Kirk Morris, Cameron Curley, Siok Tey	REAL WORLD CART (CARTRW) - Clinical, laboratory and radiological predictive factors for safety and efficacy of chimeric antigen receptor (CAR) Tcell therapy in Australia: A multi-centre real-world study	Involvement	32
Ashleigh Scott Monash University	Ashleigh Scott	AAR: Aplastic Anaemia and Other Bone Marrow Failure Syndromes Registry	Involvement	3
Caroline McNamara ALLG	Cameron Curley, Jason Butler, Elango Subramonia Pillai, Steven Lane, Kirk Morris, Nicholas Weber	ALLG AML M24 HOVON156- A phase 3, multicenter, open-label, randomized, study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by one year maintenance in patients with newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy	Involvement	0

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
Glen Kennedy ALLG	Cameron Curley, Jason Butler, Elango Subramonia Pillai, Steven Lane, Kirk Morris, Nicholas Weber	ALLG NBCR – Australasian Leukaemia and Lymphoma Group Acute Myeloid Leukaemia National Blood Cancer Registry	Involvement	10
Glen Kennedy ALLG	Cameron Curley, Elango Subramonia Pillai, Jason Butler, Kirk Morris, Nicholas Weber, Steven Lane	ALLG AMLM16: Sorafenib in Combination with Intensive Chemotherapy for Previously Untreated Adult FLT3-ITD Positive AML: A Phase 2 Randomised Double-Blind Placebo Controlled Multi-Centre Study	Involvement	0
Jane Mason QCH	Jane Mason	Rare Disease Registry Program - Gaucher, Fabry and Pompe Disease - LNR	Involvement	0
Jason Butler PMCC	Ashleigh Scott, Nicholas Weber, Cameron Curley, Elango Subramonia Pillai, Kirk Morris	PLIMATH - A multi-centre Phase II study to determine the response kinetics, safety and efficacy of pembrolizumab as frontline treatment of patients with Hodgkin Lymphoma considered unsuitable for ABVD	Involvement	0
Kirk Morris ALLG	Elango Subramonia Pillai, Ross Lindell-Innes, Stewart Hunt, Nilu Perera, Becky Leung, Nicholas Weber	ALLG NHL38 Epcor-Sandwich Study - A phase II multicentre, single arm, open-label trial of epcoritamab-containing combination salvage therapy followed by autologous stem cell transplantation and epcoritamab consolidation in patients with first relapse of large B-cell lymphoma	Involvement	1 ON HOLD 14/02/2025
Nicholas Weber MNHHS QIMRB	Andrea Henden, Steven Lane, Kirk Morris, Cameron Curley, Ashleigh Scott, Elango Subramonia Pillai, Caroline McNamara	Immune profiling of haematological malignancies	Involvement	0
Nicholas Weber ALLG	Kirk Morris, Caroline McNamara, Elango Subramonia Pillai, Cameron Curley, Ross Lindell-Jones	ALLG HD13 RADAR - A randomised phase III trial with a PET response adapted design ABVD +/- ISRT and A2VD +/- ISRT in patients with previously untreated stage IA/IIA Hodgkin lymphoma	Involvement	1
Nicholas Weber The Myeloma and Related Diseases Registry	Jason Butler	MRDR - Myeloma and Related Diseases Registry	Involvement	19
Nicholas Weber AMaRC (Australasian Myeloma Research Consortium)	Kirk Morris; Caroline McNamara; Jason Butler	AMARC 19-02 BelaCarD - A phase I/II single arm study of combination Belantamab Mafodotin, Carfilzomib, Dexamethasone in patients with early relapsed multiple myeloma	Involvement	0
Nicholas Weber AMaRC (Australasian Myeloma Research Consortium)	Ashleigh Scott, Cameron Curley, Jason Butler, Ross Lindell-Jones	AMARC RIDDLE-M-X trial - Risk Directed Front-Line Therapy for Multiple Myeloma incorporating Selinexor	Involvement	2
Nicholas Weber AMaRC (Australasian Myeloma Research Consortium)	Jason Butler, Kirk Morris, Nilu Perera, Ross Lindell-Innes, Sean McKeague, Stewart Hunt	AmaRC 24-01 ZEPFHR:MM - A Centralized Platform study for Functional High Risk Multiple Myeloma - AMaRC 24-01	Involvement	1

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
Nicholas Weber PMCC	Nicholas Weber	Red Cross Retro: Assessing the risk of alloimmunisation in patients treated with Daratumumab	Involvement	0
Nilu Perera ALLG	Caroline McNamara; Ashleigh Scott, Nicholas Weber, Kirk Morris, Ross Lindell-Innes, Stewart Hunt	ALLG CML14 ASCENDENCE - ASCiminib Evaluation in Newly diagnosed CML with Dasatinib to Augment response in Complex genomic aetiology	Involvement	3
Siok Tey Westmead Institute of Medical research	Ashleigh Scott, Andrea Henden, Cameron Curley, Elango Subramonia Pillai, Jason Butler	R3ACT Randomised (R3R) - A randomised trial of most closely HLA-matched third-party donor-derived virus-specific cytotoxic T-lymphocytes in patients with untreated viral infection post-allogeneic stem cell transplantation	Involvement	0 ON HOLD 03/11/2023
Siok Tey ALLG	Jason Butler, Cameron Curley, Glen Kennedy, Ashleigh Scott, James Morton, Elango Subramonia Pillai, Andrea Henden	ALLG BM12 CAST: Study of using Cyclophosphamide After Sibling-donor allogeneic stem-cell Transplantation (CAST) in patients with acute leukaemia and myelodysplasia: a randomised study comparing cyclosporin and methotrexate to cyclosporin and post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis.	Involvement	0
Steven Lane ALLG	Caroline McNamara; Elango Subramonia Pillai; Kirk Morris; Nicholas Weber	ALLG CML 13 ASCEND - A single arm phase II study to evaluate the efficacy of asciminib in newly diagnosed patients with chronic phase chronic myeloid leukaemia	Involvement	0
Steven Lane ALLG	Cameron Curley, Jason Butler, Kirk Morris, Nicholas Weber, Elango Subramonia Pillai	LS17 REGALLIA: Studies to delineate the molecular and genomic basis of high risk ALL (Registry of Acute Lymphoblastic Leukaemia in Australasia and Associated Correlative Studies)	Involvement	0 ON HOLD 13/09/2024
Steven Lane ALLG	Kirk Morris, Andrea Henden, Caroline McNamara, Nilu Perera, Siok Tey	AML26 INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm, Precision-based, Recursive, Platform Trial	Involvement	15
Steven Lane ALLG	Caroline McNamara, Elango Subramonia Pillai, Nilu Perera, Kirk Morris, Stewart Hunt	ALLG AML27 Impress A phase II study evaluating the efficacy and safety of imetelstat in patients with HR myelodysplastic syndromes or AML failing HMA-based therapy	Involvement	0
Steven Lane SAHMRI	Andrea Henden, Cameron Curley, Caroline McNamara, Kirk Morris, Nicholas Weber	PREACH-M - Precision Medicine for Chronic Myelomonocytic Leukaemia: A phase II Trial Studying the Efficacy of Lenzilumab and High Dose Ascorbate with Azacitidine Based on Molecular Profiling	Involvement	1
Steven Lane	Glen Kennedy	P1382 - Examination of genes that control the growth and survival of blood cancers	Involvement	0

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
Steven Lane The University of Sydney	Nicholas Weber, Cameron Curley, Kirk Morris	MoST Framework - The Cancer Molecular Screening and Therapeutics (MoST) Program - A framework protocol for multiple, parallel, signal-seeking clinical studies of novel molecularly targeted therapies for patients with advanced cancer and unmet clinical need.	Partnership	0
Steven Lane Australian Genomic Cancer Medicine Group, OMICO, NHMRC	Andrea Henden, Cameron Curley, Caroline McNamara, Kirk Morris, Nicholas Weber	MoST LLY 15 AZ - A single arm, open label, signal seeking, phase II trial of the activity of Durvalumab in combination with Acalabrutinib in patients with high-grade B cell lymphoma	Partnership	0
Steven Lane Australian Genomic Cancer Medicine Group, OMICO, NHMRC	Andrea Henden, Cameron Curley, Caroline McNamara, Kirk Morris, Nicholas Weber	MoST LLY 16 BGB - AZ - A Single arm, open label, signal seeking, phase II trial of pamiparib in patients with relapsed/ refractory myeloid haematological malignancy with aberrant germline or somatic DNA repair pathway function	Partnership	0
Jason Butler PMCC (Peter MacCallum Cancer Centre)	Cameron Curley, Elango Subramonia Pillai, Kirk Morris, Ashleigh Scott, Siok Tey, Andrea Henden, Ross Lindell-Jones	PMCC COALITION - A multicentre, parallel arm, open-label trial of frontline R-CHOP/Pola-RCHP and glofitamab in younger, higher risk patients with diffuse large B cell lymphoma (DLBCL)	Involvement	0

Research Publications

Authors

Investigator	ORCID ID
Andrea Henden	https://orcid.org/0000-003-2261-169X
Siok Tey	https://orcid.org/0000-0001-9567-382X
Ashleigh Scott	https://orcid.org/0000-0001-5574-6713
Nick Weber	https://orcid.org/0000-0001-6341-2537
Michelle Spanevello	https://orcid.org/0000-0003-1498-7822
Steven Lane	https://orcid.org/0000-0002-8050-6209
Jane Mason	https://orcid.org/0000-0002-8320-2884
Stewart Hunt	https://orcid.org/0000-0002-4555-6964
Nilu Perera	https://orcid.org/0000-0002-4752-0551
Associate Professor Glen Kennedy	https://orcid.org/0000-0002-7171-0435
Sally Campbell	https://orcid.org/0000-0002-1421-745X
Caroline McNamara	https://orcid.org/0000-0002-1116-9747
Joseph Noye	https://orcid.org/0000-0002-4422-3375
Jason Butler	https://orcid.org/0000-0002-6422-4404
Kirk Morris	https://orcid.org/0009-0003-2446-1098
Antoinette Runge	https://orcid.org/0009-0000-7543-3706
Ross Lindell-Innes	https://orcid.org/0009-0004-4044-1369
Sean McKeague	https://orcid.org/0000-0002-3280-0120

Publications in 2025

Journal Articles (RBWH staff or consumers in bold)

Ozelo MC, **Mason J**, Dunn AL, Villaça PR, Shen MC, Agarwal S, Imtiaz U, Liu H, Robinson TM. Safety and efficacy of valoctocogene roxaparvovec with prophylactic glucocorticoids: 1-year results from the phase 3b, single-arm, open-label GENER8-3 study. J Thromb Haemost. 2025 Jan 10:S1538-7836(25)00002-9. doi: 10.1016/j.jtha.2024.12.038. Epub ahead of print. PMID: 39800255.

Zulekha Khan, **Glen A Kennedy, Ashleigh P Scott, Cameron Curley**, John Kwan, Kate Melville, Rebecca Booth, Ashish Bajel, David S. Ritchie, Katherine Cummins, John Moore, Peter Bardy, Naranie Shanmuganathan, Shaun Fleming, Bianca Cirone, Julian Cooney, William Jackson, David Kliman, Julija Sipavicius, Edward Abadir, Bartlomiej Getta, Ian Michael Irving, Hock Choong Lai, Eric Wong, Leonie Wilcox, Steven Tran, Nada Hamad; Rural/Regional Place of Residence Impacts Post Allogeneic Bone Marrow Transplant Overall Survival of Australian Patients with Acute Myeloid Leukaemia: An Anztct Registry Study. Blood 2024; 144 (Supplement 1): 7923. <https://doi.org/10.1182/blood-2024-204669>

Ricky Nelles, Jason Butler, Cameron Curley, Andrea S Henden, Stewart Hunt, James Morton, Elango Subramoniapillai, Caroline Stewart, Siok-Keen Tey, Glen A Kennedy, Ashleigh P Scott; Allogeneic Haematopoie Stem Cell Transplantation Is Safe and Effective for Myeloid Neoplasms with Germline DDX41 Mutation. Blood 2024; 144 (Supplement 1): 7439. <https://doi.org/10.1182/blood-2024-209669>

Journal Articles (RBWH staff or consumers in bold)

Becky Leung, Jason Butler, Cameron Curley, Andrea S Henden, Stewart Hunt, James Morton, Elango Subramoniapillai, Caroline Stewart, Siok-Keen Tey, Glen A Kennedy, Ashleigh P Scott; Real World Outcomes of Ruxolitinib Treatment of Steroid Refractory/Dependent Acute Graft Versus Host Disease. *Blood* 2024; 144 (Supplement 1): 7351. <https://doi.org/10.1182/blood-2024-210424>

Miles Horton, **Becky Leung, Ricky Nelles**, Matthew Rubic, Christopher McKinnely, Alia Cibich, Mark R Dowling, **Stewart Hunt**, Lynette C.Y. Chee, **Ashleigh P Scott**, David S. Ritchie, Devendra Hiwase, Duncan Purcell, Abir Bhattacharya, **Glen A Kennedy**, Ashish Bajel; Prior Azacitadine and Ongoing Transfusion Dependence in MDS Patients Are Associated with Inferior Survival after Allogeneic Stem Cell Transplant. *Blood* 2024; 144 (Supplement 1): 7440. Doi: <https://doi.org/10.1182/blood-2024-209705>

Young G, Lassila R, **Mason J**, Prasca S. Deconstructing the ISTH hemophilia guidelines for the clinician. *JTH IN CLINIC*. 2024. Doi: <https://doi.org/10.1016/j.jtha.2024.11.015>

Vickers D, Martynychuk A, **Henden A**, Smibert OC, Hawkes EA and Chong G. The gut microbiome in B cell lymphoma. *Blood Reviews*, 2025 Dec 9:101357. <http://doi.org/10.1016/j.blre.2025.101357>. Online ahead of print.

Lindsay J, Yeoh D, Teh BW, Reynolds GK, **Henden AS**, McQuilten Z, Wheeler M, Hamilton A, Nelson A, **Nakagaki M**, Sandhu S, Slavin MA. Australasian Neutropenic Fever Guidelines Steering Committee. Consensus guidelines for antibacterial prophylaxis in patients with neutropenia. *Intern Med J*. 2025 Dec;55 Suppl 7:115-135. <https://doi.org/10.1111/imj.70250>. PMID: 41521409.

Pearce J, Visscher L, **Karlovic N, Halliday B, Mason J**. Hand and Foot Subungual Haematomas in Haemophilia: A Report of Six Cases. *Haemophilia*. 2025 Jun 2. doi: 10.1111/hae.70059. Epub ahead of print. PMID: 40452506. <https://doi.org/10.1111/hae.70059>

Pastore G, Robertson J, **Campbell S, Mason J**. Early Emicizumab Treatment in Acquired Hemophilia A: Impact on Bypassing Agent Use and Length of Hospitalization in an Australian Single-Center Cohort. *Semin Thromb Hemost*. 2025 Jun 17. doi: <https://doi.org/10.1055/a-2622-3483>. Epub ahead of print. PMID: 40527348

Andersen S PhD, Adv APD, **Kennedy GA**, Banks M, Flanagan BM BSc (Hons) PhD, **Henden AS**. Prebiotic fibre enteral supplementation post allogeneic transplantation; feasibility and impact on the microbiome. *Blood Adv*. 2025 Jun 9 :bloodadvances.2024015703. <https://doi.org/10.1182/bloodadvances.2024015703>. Epub ahead of print. PMID: 40489796

Curtis DJ, Patil SS, Reynolds J, Purtill D, Lewis C, Ritchie DS, Gottlieb DJ, Yeung DT, Wong E, **Tey SK**, Perera T, Moore J, Koldej RM, De Abreu Lourenco R, Stubbs J, Morrissey CO, Munsef N, Arenas A, Hill GR; Australasian Leukaemia and Lymphoma Group. Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin. *N Engl J Med*. 2025 Jun 13. <https://doi.org/10.1056/NEJMoa2503189>. Epub ahead of print. PMID: 40513032

Henden AS, Lineburg KE, Panikkar A, Mahajan A, Nelles R, **Wright E**, Crooks P, Raju J, Texier LL, Swaminathan S, Beagley L, Best S, Solomon M, Reddiex H, **Kennedy G, Tey S**, Neller MA, Khanna R & Smith C. Allogeneic off-the-shelf SARS-CoV-2-specific adoptive T-cell therapy for refractory. *Clinical & Translational Immunology*. 2025 Jun 14. doi: <https://doi.org/10.1002/cti2.70038>.

Hajkowicz K, Woodford J, **Pillai E, Henden A**, Lowry K, Petrone ME, Patrick NA, Holmes H, Holmes EC. Meta transcriptomic Identification of Trubanaman Virus Sequences in Patient with Encephalitis, Australia. *Emerging Infectious Diseases*. 2025;31(12):2332-2335. <https://doi.org/10.3201/eid3112.251190>

Bywater MJ, Haldar R, Janardhana Y, Cooper E, Cooper L, Chang SHN, Hayes NJ, Ling V, Straube JM, **Lane SW**. Bcl-xL inhibition potentiates interferon-induced apoptosis in MPN stem cells. *Blood Advances* 2025, Nov 25. Vol 9, Iss 22 <https://doi.org/10.1182/bloodadvances.2025017242>. Online ahead of print PMID: 40864222

Sheehy J, Gallanagh M, Sullivan C, **Lane SW**. Clinical prediction models for febrile neutropenia and its outcomes: a systematic review. *Supportive Care in Cancer* 2025 June, vol 33, Iss 537. <http://doi.org/10.1007/s00520-025-09562-y>

Yuan Y, **Lane SW**. Prevention, Diagnosis and management of myeloproliferative neoplasms. *Haematologica* 2025 Apr, Vol 10, Iss 4; 825-7. <https://doi.org/10.3324/haematol.2024.285414>

Sheehy J, **Scott AP, Henden AS, Kennedy G**, Redmond AM & Stewart AG. Low rates of complications and β -lactam resistance in viridans group streptococci bloodstream infection among cancer patients receiving chemotherapy. *The Journal of Antimicrobial Chemotherapy*. 2024 Jul 8. <https://doi.org/10.1093/jac/dkae209>. Online ahead of print. PMID: 38973602

Barge L, Tran S, **Kennedy G**, Ritchie D, Gottlieb D, Milliken S, Spencer A, Purtill D, Perera T, Doocey R, Larsen S, Butler A, Bardy P, Greenwood M, Durrant S, **Curley C**, Stewart C, Tam C, Balendran S, Di Ciaccio PR, Patil S, Han MH & Hamad N. Outcomes of allogeneic haemopoietic transplant for chronic lymphocytic leukaemia in the modern era. *Internal Medicine Journal*. 2025 May 3. <https://doi.org/10.1111/imj.70050>. Online ahead of print

Nakagaki M, Hajkowicz K, Roberts JA, Henden AS. Cause and effect? A review of the impact of antibiotics on the gut microbiome in patients undergoing hematopoietic stem cell transplantation. *Expert Rev Anti Infect Ther*. 2025 Jul 6:1-14. <https://doi.org/10.1080/14787210.2025.2527970>. Online ahead of print. PMID: 40591953

Ho PJ, Quach H, Sidiqi MH, Lee CH, **Butler J**, Spencer A, Micklethwaite K, Li J, Cusson E, Bagnall R, Harrison SJ. Management of CAR-T cell therapy in patients with multiple myeloma: a systematic review and expert consensus in Australia. *Front Oncology*. 2025 Jan 21. <https://doi.org/10.3389/fonc.2024.1535869>. Online ahead of print

Keynote or Plenary Lectures given in 2025

Date	Title
June 2025	Deconstructing the ISTH Haemophilia guidelines International Society of Thrombosis and Haemostasis conference - Washington DC, USA. Dr J Mason
August 2025	"Beyond Chemobrain: assessing neurologic toxicity during blood cancer therapy" Statewide Neurosciences Seminar. Dr A Scott
05th August 2025	"Cellular Therapies in Mantle Cell Lymphoma"; ANZTCT ASM. Dr A Henden
05th August 2025	"Double Refractory CLL"; ANZTCT) Annual Scientific Meeting (ASM). Dr S. McKeague
06th August 2025	"Long-term outcomes following allogeneic HSCT for Severe Aplastic Anaemia"; (ANZTCT) Annual Scientific Meeting (ASM). Dr A. Scott
08th August 2025	"Discussing the Phase 2 clinical trial results for the drug CYP-001. The trial focused on using the therapy to treat high-risk acute graft-versus-host disease (HR-aGvHD), a complication following bone marrow transplants", (ANZTCT) Annual Scientific Meeting (ASM). Dr A. Scott
08th August 2025	"A Multicentre, Randomized, Double-blind, Placebo-Controlled Phase 2 Study to Investigate the Efficacy and Safety of CYP-001 in Combination with Corticosteroids vs Corticosteroids Alone for the Treatment of High-Risk Acute Graft Versus Host Disease (aGvHD)". (ANZTCT) Annual Scientific Meeting (ASM). Dr A Scott
15th August 2025	"Phase I clinical trial using place-of-care "fresh in, fresh out" CD19 CAR T cells"; International Society for Cell and Gene Therapy, Australia New Zealand (ISCT ANZ) Regional Meeting. Sydney. Dr S Tey
05th September 2025	"CAR-T toxicities and secondary immunodeficiency"; Australian Society of Clinical Immunology and Allergy (ASCIA) Conference. Brisbane. Dr S Tey

Radiation Oncology

Research highlights



Dr Penny Mackenzie

Director Radiation Oncology

The culture of interdisciplinary collaboration and technological advancement remained a defining strength of Radiation Oncology throughout 2025. The aim and focus of the Radiation Oncology Research group is to promote, support and drive innovation, promote quality initiatives and ensure quality improvement projects deliver evidence-based practice, to ensure safe treatment delivery.

As new and emerging technologies are rapidly being assimilated into daily practice, the focus of research outcomes is to implement new technology in a scientific manner. Quality assurance and research into new technology is important to ensure precision radiotherapy is delivered in a safe, efficient, and cost-effective manner.


In 2025, the Radiation Oncology team continued to expand its broad research program, supported by seven active research grants. The department served as lead investigator on 19 current research projects and collaborated with other RBWH departments and external organisations on an additional 24 projects. Research output remained strong, with the department contributing actively to publications and peer-reviewed journal articles.

Research highlights from 2025 include:

- Dr Penny Mackenzie, Director of Radiation Oncology, successfully completed a PhD titled Geriatric Oncology and Radiotherapy utilisation. Dr Mackenzie's research and professional contributions demonstrate a strong focus on geriatric oncology, especially understanding and improving radiotherapy utilisation among older adults.
- Dr Liting (Nancy) Yu in the radiation oncology medical physics group successfully completed a PhD, with the thesis "Developing new methods of dose evaluation for VMAT patient specific plans" under the supervision of Scott Crowe and Tanya Kairn. The thesis included 5 first-authored publications, and Nancy published a further 5 papers during the PhD candidature. Nancy completed the PhD while enrolled part-time, with support from the RBWH and RBWH Foundation.
- Professor Lizbeth Kenny (AO) was awarded the Metro North Chief Executives award for her four-decade career that has improved the care, treatment, and technology used to diagnose and treat cancers.
- The I-CARE Clinical Trial team was the recipient of the Research Support Award at the 2025 Metro North Research Excellence Awards held in September, in recognition of their outstanding dedication and contribution to research excellence.
- The cPOST trial was published in *New England Journal Medicine* showing improvement of disease-free survival with the addition of adjuvant Cemiplimab for high-risk cutaneous squamous cell carcinoma. RBWH contributed to the accrual of this important landmark trial.

Looking ahead, 2026 will be another active year for research. Several manuscripts are in progress and will be published soon. In-house projects led by our radiation therapists, physicists and national/international collaborative projects introduced to the department by the Radiation Oncologists are being designed and rolled out in the coming months. Finally, we like to whole heartedly thank our patients who participate in our trials to make clinical research possible.

Successful Research Higher Degree (e.g. MPhil or PhD) candidates in 2025

Name	Degree (e.g. MPhil or PhD)	Title	Month Completed	Affiliated University	Summary
Dr Liting (Nancy) Yu 	PhD	Developing new methods of dose evaluation for VMAT patient specific plans	March 2025	Queensland University of Technology	DOI: 10.5204/thesis.eprints.255823
Dr Penny Mackenzie 	PhD	Geriatric Oncology and Radiotherapy Utilisation	October 2025	The University of New South Wales	DOI: 10.26190/unsworks/31643

Research Awards and Achievements

Recipient (RBWH staff in bold)	Award	Event
Integrated Cancer REsearch (I-CARE) Collaborative – Clinical Trials	Research Support Award	Metro North Health (2025 Research Excellence Awards)
Professor Lizbeth Kenny (AO)	Metro North Chief Executives Award	Metro North Staff Excellence Awards 28/11/2025

Research Grants

Investigator Names (RBWH staff in bold)	RBWH Departments / Research Groups	Research Project Title	Granting Body	Total Awarded (whole all years)	Length of Awards in years and years active
K Fong, I Yang, H Marshall, R Bowman, R O'Rourke, P Valery, E Stone, R Manser, K Canfell, M Weber, G Garvey, S Lam, M Tammemagi, S Sabesan, Z Otty, F Brims, A McWilliams, B Page, J De Laat, S Hambleton, G Pratt, P Chan , M Windsor, R Naidoo, B Hughes, Z Lwin, K Hopcraft, M Toombs, P Fogart, P Tobias, B Bartholmai, F Maldonado, F Martignano, S Conticello, P Grogan, L Passmore, A Dent, G Olive, B Parris, H O'Farrell, K Chee	MNH, DRO, DM	Improving outcomes for people with and at risk of lung cancer	Australian Cancer Research Foundation (ACRF)	\$2,000,000	4 years 2022-2025
Agar M, Hayen A, Viney R, Knox N, Vinod S, Krasovitsky M, Blackberry I, Steer C, Moth E, Blinman P, Soo K, to T, Morris L, Mackenzie P	CCS DRO	Delivering better care for older Australians with cancer.	Medical Research Future Fund (MRFF) – Applied Research in Health	\$1,468,223.13	4 years 2024-2028
Punyadeera C, Kenny L, Sriram S, Hughes B, Leo P	CCS DRO, DMO	Multi-analyte liquid biopsy-based biomarkers for oropharyngeal cancer	NHMRC	\$763,417.40	4 years 2022-2025
Scott Crowe, Paul Charles, Elise Obereigner, Rachael Wilks, Lee Heseltine, Graeme Dickie, Catherine Bettington, Philip Chan, Steven Sylvander, Tanya Kairn, Glen Kennedy	CCS DRO	Improving radiation oncology with 3D printing and Biofabrication	Herston Biofabrication Institute program grant	\$515,000	7 years 2019-2025

Investigator Names (RBWH staff in bold)	RBWH Departments / Research Groups	Research Project Title	Granting Body	Total Awarded (whole all years)	Length of Awards in years and years active
Chamindie Punyadeera, Lizbeth Kenny	CCS DRO	A novel assay for early detection of minimal residual disease in head and neck cancer patients	Garnett Passe & Williams	\$375,000	4 years 2022-2025
Charles Lin	CCS DRO	A prospective study investigating the efficacy and toxicity of definitive chemoradiation and immunotherapy (CRIO) in locally and / or regionally advanced cutaneous squamous cell carcinoma	Astra Zeneca	\$211,000	10 years 2017-2027
Mackenzie P	CCS DRO	Queensland Cancer Council Clinical Trial Data Manager Grant 2024	Queensland Cancer Council	\$23,000	1 year 2025

RBWH Department / Research Group Led Research Activity

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
Charles Lin	Benjamin Chua, Lizbeth Kenny, Michelle Nottage, Brett Hughes, Michele Teng, Paul Thomas	A prospective study investigating the efficacy and toxicity of definitive chemoradiation and immunotherapy (CRIO) in locally and / or regionally advanced cutaneous squamous cell carcinoma	Involvement	0
Jemma Walsh (nee Devereaux)	Jemma Blyth, Elena Blyth, Gregory Rattray, Catriona Hargrave, Lisa Nissin, Julie Burbery	DIBH (Deep Inspiration Breath Hold)-BREaST Trial. Breath Hold Respiratory Endurance & Spirometry Training	Involvement	Phase 1 – 15 Phase 2 - 41
Emilie Crosier	Alice Grigg, Teresa Brown, Judy Bauer, Jeffrey Goh, Phillip Chan	Dietary counselling to increase soluble fibre in patients with gynaecological cancer undergoing pelvic radiotherapy: a feasibility study	Involvement	
Jemma Blyth, Kevina Choma	Michelle Grogan, Emily Simpson-Page, Naasiha Cassim, Cathy Hargrave, Scott Crowe	Evaluation of a commercially available treatment bra during radiation therapy for breast cancer patients with large or pendulous breasts	Involvement	
Scott Crowe	Paul Charles, Elise Obereigner, Tania Poroa, Jenna Luscombe, Rachael Wilks, Lee Heseltine, Graeme Dickie, Catherine Bettington, Philip Chan, Steven Sylvander, Tanya Kairn	Improving radiation oncology with 3D printing and Bio fabrication	Consultation	N/A (~50 in HREC approved study so-far – retrospective)
Scott Crowe	Susie Cleland, Sarah Maxwell, Tania Poroa, Paul Charles, Tanya Kairn	Evaluation of 3D scanning systems for radiotherapy use	Consultation	N/A (28 healthy volunteers)
Scott Crowe	Liting Yu, Alex Livingstone, Samuel Peet, Tanya Kairn	Characterising the relationship between radiotherapy treatment plan parameters and routine quality assurance test results	Consultation	N/A (retrospective)

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
Liting Yu	Tanya Kairn, Alex Livingstone, Scott Crowe, Jamie Trapp	Structure based dose distribution comparison	Consultation	N/A (retrospective)
Charles Lin	Charles Lin, Megan Carroll, Ryan Somerville, Sarah Grigg	Carcinoma of Head and Neck with Perineural spread: Outcomes After Skull Base Surgery and Adjuvant Radiotherapy	Consultation	N/A (retrospective)
Rachael Wilks	Scott Crowe, Tanya Kairn, Philip Chan, Robyn Cheuk	Design of a patient-matched vaginal applicator for brachytherapy treatments	Involvement	N/A
Kate Stewart	Izaak Millen, Crispin Chamunyonga, Neil O'Brien	Evaluation of patient position on heart and lung doses in breast cancer radiation therapy	Consultation	N/A (retrospective)
Kate Stewart	Samuel Peet, Jeremy Briggs, Benjamin Chua	Evaluation of the correlation between optical and thermal surface tracking and kV x-ray imaging during cranial radiotherapy	Consultation	N/A (retrospective)
Scott Crowe	Keya Amarsee, Samuel Peet	Dose calculation and comparison for superficial treatment modalities	Consultation	N/A (retrospective) Awaiting HREA approval
Scott Crowe	Tanya Kairn, Brodie Milsom	Evaluation of dosimetric perturbation in and around synthetic scaffolds in breast radiotherapy	Consultation	N/A
Veronica Tippet		Retrospective Audit of Image Guided Radiation Therapy Practices at the RBWH	Consultation	Awaiting HREA approval
Scott Crowe	Jemma Walsh, Nancy Yu, Philip Chan, Rachel Effene, Gregory Rattray, Tanya Kairn	Radixact Synchrony performance data collection and analysis	Consultation	N/A
Kevina Choma	Kate Stewart, Cathy Hargrave, Natalie Pollard, Grace Wright	An evaluation of accuracy and efficiency of ExacTrac Dynamic pre-positioning versus tattoo-based positioning for chest radiation therapy	Consultation	N/A (retrospective)
Jemma Blyth	Kate Stewart, Philip Chan, Robyn Cheuk, Rachael Wilks, Craig Lancaster, Julie-Anne Outhwaite, Clare Berry, Katie McMahon, Cathy Hargrave, Julie Burberry, Trinioty Murfett, Kylee Burton, Nuala Clinton, Sue Hewitt, Michelle Connors	Evaluation of magnetic resonance imaging protocols for radiation therapy treatment planning of gynaecological cancers	Involvement	0 (awaiting HREA submission)
Anthony Pagidas, Jemma Blyth, Charles Lin, Philip Chan	Rachel Effene, Cathy Hargrave, Michael Gray, Carlyn McDonnell, Emma Anderson, Clare Blake, Tamara Wolf	Bowel and bladder preparation for prostate cancer patients at the Royal Brisbane and Women's Hospital. Feasibility of patient centric education approach.	Involvement	0 (awaiting HREC approval)

Collaborative Research Activity Involving RBWH Department / Research Group

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
Associate Professor Hien Le	Robyn Cheuk	Australian Particle Therapy Clinical Quality Registry (ASPIRE)	Partnership	0

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
Mariana Carbini	Philip Chan	An International, Prospective, Open-label, Multi-centre, Randomized Phase III Study comparing lutetium (177Lu) vipivotide tetraxetan (AAA617) versus Observation to delay castration or disease recurrence in adult male patients with prostate-specific membrane antigen (PSMA) positive Oligometastatic Prostate Cancer (OMPC) (PSMA-DC)	Involvement	0
Dr Rachael Dodd	Lizbeth Kenny	Helping clinicians and patients make sense of HPV-related oropharyngeal cancer: implementation of an information resource. X24-0033	Consumer-Led	0
Miryana Dimova-Dobrev	Philip Chan	ARASTEP A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Darolutamide Plus Androgen Deprivation Therapy (ADT) Compared with Placebo Plus ADT in Patients With High-risk Biochemical Recurrence (BCR) of Prostate Cancer	Involvement	0
Shankar Siva	Charles Lin	DECREASE TROG 19.06 Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer detected by PSMA	Partnership	0
Jarad Martin	Charles Lin, Philip Chan, Robyn Cheuk, Rachel Effene, Michelle Grogan, Gary Pratt	NINJA TROG 18.01 Novel Integration of New prostate radiation schedules with adjuvant Androgen deprivation	Partnership	7
Fiona Day, Jarad Martin	Melissa Eastgate, Samantha Barbour	PALEO Phase II clinical trial of chemo radioimmunotherapy for the ALleviation of oEsOphageal cancer complications	Partnership	1
Andrew Scott Eng-Siew Koh	Benjamin Chua	TROG 18.06 Prospective, multicentre trial evaluating FET-PET in Glioblastoma (FIG)	Partnership	2
Alison Brand	Philip Chan	A phase II pilot study of the use of vaginal oestriol to prevent vaginal stenosis in patients treated with radiotherapy for gynaecological, rectal and anal malignancies (VESPA)	Involvement	0
Christopher Sweeney, Tamim Niazi	Philip Chan	DASL-HiCaP: Darolutamide Augments Standard Therapy for Localized High-Risk Cancer of the Prostate (ANZUP1801). A randomized phase 3 trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in high risk, clinically localized prostate cancer	Involvement	0
Danny Rischin	Charles Lin	A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo after Surgery and Radiation Therapy in Patients with High-Risk Cutaneous Squamous Cell Carcinoma (C-POST)	Involvement	0

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
Sherene Loi	Robyn Cheuk Michelle Grogan	TROG 17.05 A randomised phase II trial comparing the efficacy of single fraction or multi-fraction SABR (Stereotactic ablative body radiotherapy) with Atezolizumab in patients with advanced Triple negative breast Cancer (AZTEC)	Partnership	0
Michael Jenkinson	Catherine Bettington	TROG 15.02 Radiation versus Observation following surgical resection of Atypical Meningioma: a randomised controlled trial (ROAM)	Partnership	0
Vincent Grégoire	Lizbeth Kenny	TROG 14.03 (EORTC-1219-ROG-HNCG) A blind randomized multicentre study of accelerated fractionated chemo-radiotherapy with or without the hypoxic cell radiosensitizer nimorazole (Nimoral), using a 15 gene signature for hypoxia in the treatment of squamous cell carcinoma of the head and neck	Partnership	0
Danny Rischin	Lizbeth Kenny	TROG 12.01 A randomised trial of Weekly Cetuximab and Radiation Versus Weekly Cisplatin and Radiation in Good Prognosis Locoregionally Advanced HPV-Associated Oropharyngeal Squamous Cell Carcinoma	Partnership	0
Chamindie Punyadeera	Lizbeth Kenny	A simple saliva test to diagnose head and neck cancer at an early stage - head and neck cancer detection is a spitting distance away	Involvement	19
Rajiv Khanna	Lizbeth Kenny	P2191 Development of an Adoptive T Cell Therapy for HPV-Associated Malignancies	Involvement	2
Boon Chua	Lizbeth Kenny	TROG 07.01 A randomised phase III study of radiation doses and fractionation schedules in non-low risk ductal carcinoma in situ (DCIS) of the breast	Involvement	0
David Pryor	Charles Lin	TROG 16.03: A multistage multi centre international randomised trial of Conventional care Or Radioablation (stereotactic body radiotherapy) for Extra-cranial oligometastatic disease in lung, breast and prostate cancer (CORE)	Partnership	0
Shankar Siva	Charles Lin	TROG 15.03 Focal Ablative STereotactic RADiosurgery for Cancers of the Kidney - A Phase II Clinical Trial (FASTRACK II)	Partnership	0
Scott Williams Paul Nguyen	Philip Chan	Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostate cancer: ENZARAD	Involvement	0

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
Peter Graham	Robyn Cheuk	TROG 08.06 A randomised comparison of anastrozole commenced before and continued during adjuvant radiotherapy for breast cancer versus anastrozole and subsequent anti-oestrogen therapy delayed until after radiotherapy. (STARS - Study of Anastrozole and Radiotherapy Sequencing)	Partnership	0
Katie McMahon	Briley Devenport, Cathy Hargrave, Kate Stewart , Julie Burbery	The feasibility of utilising total body photography in superficial radiation therapy to assist in target volume definition planning and documentation.	Involvement	N/A
Crispen Chamunyonga	Cathy Hargrave, Kerrie Mengersen, Kate Stewart, Gregory Rattray	Development of a framework for systematic contour evaluation in radiation therapy	Consultation	N/A (retrospective)

Research Publications

Authors

Investigator	ORCID ID
Benjamin Chua	https://orcid.org/0000-0002-0377-9844
Catherine Bedlington	https://orcid.org/0000-0002-8227-6320
Charles Lin	https://orcid.org/0000-0001-5589-4775
Craig Lancaster	https://orcid.org/0000-0002-8797-9586
Gary Pratt	https://orcid.org/0000-0001-5296-3990
Gregory Rattray	https://orcid.org/0009-0000-4747-8464
Jemma Walsh	https://orcid.org/0009-0009-6439-9413
Kate Stewart	https://orcid.org/0000-0001-8676-6565
Kirby Francis	https://orcid.org/0000-0002-4285-1255
Liting (Nancy) Yu	https://orcid.org/0000-0002-1264-9996
Lizbeth Kenny	https://orcid.org/0000-0002-7556-0542
Naasiha Cassim	https://orcid.org/0000-0002-8671-5909
Penny Mackenzie	https://orcid.org/0000-0003-4365-6977
Philip Chan	https://orcid.org/0000-0002-6596-5570
Rachael Wilks	https://orcid.org/0000-0002-2110-9676
Rachel Effeney	https://orcid.org/0000-0002-6684-2601
Robyn Cheuk	https://orcid.org/0000-0001-9516-5526
Samuel Peet	https://orcid.org/0000-0003-4817-4256

Sarah Maxwell	https://orcid.org/0000-0003-4817-4256
Scott Crowe	https://orcid.org/0000-0001-7028-6452
Sharon Gordon	https://orcid.org/0000-0002-3273-9083
Tania Poroa	https://orcid.org/0000-0002-8636-5793
Tanya Kairn	https://orcid.org/0000-0002-2136-6138

Publications in 2025

Journal Articles (RBWH staff or consumers in bold)

Brown T, Cooney L, Smith D, Elvin-Walsh, L., Kern E., Ahern S, Brown B, Hickman I, Porceddu, S, **Kenny L & Hughes, B.** (2026). Comparison of Prophylactic Versus Reactive Tube Feeding Approaches on Weight Loss and Unplanned Hospital Admissions in Patients with Head and Neck Cancer Receiving Chemoradiotherapy. *Current Oncology*, 33(1), 5. <https://doi.org/10.3390/curroncol33010005>

Crowe SB, Walsh J, Rattray G, Chan P, Kairn T. Use of Motion Management to Model Unmanaged Motion: Dosimetric Consequences of Unmanaged Prostate Motion Assessed Using Real-Time Radiotherapy Adaptation Data. *Cureus*. 2025 Apr 20;17(4):e82620. doi: 10.7759/cureus.82620. PMID: 40395244; PMCID: PMC12090664.

Damodaran S, Weeramange C.E, **Kenny L**, Vasani, S, **Hughes B**, Breik O & Punyadeera Circulating tumour cells and circulating tumour DNA in head and neck cancer: from molecular insights to clinical impact. *Cancer Metastasis Rev* **44**, 88 (2025 Dec 4). <https://doi.org/10.1007/s10555-025-10305-y>

Devonport B, Burberry J, McMahon K.L, **Stewart, K.** and Hargrave, C. (2025), The Feasibility of Total Body Photography (TBP) in Superficial Radiation Therapy (SXRT). *J Med Radiat Sci*, 72: 473-482 <https://doi.org/10.1002/jmrs.70012>

Fielding D, Sidhu C, Alkhater M, Alawami M, Kops SEP, van der Heijden EHFM, Bashirzadeh F, Windsor M, Nixon E, Son JH, Ananda Setty N, Pattison DA, Fong W, Bhatt M, Dhiantravan N, Ramsay S, Boots R, **Pratt G, Bettington C**, Francis R, Thomas P, Steinke K, Thomas R. Biopsy decision for intermediate-high-risk lung nodules is significantly changed when guided by prior positron emission tomography/CT (PET/CT) results: results of the prospective PET-FIRST study. *BMJ Open Respir Res*. 2025 Jun 1;12(1):e002553. doi: 10.1136/bmjresp-2024-002553. PMID: 40451293; PMCID: PMC12142131.

Gordon SR, Crowe SB, Walsh J, Bettington CS, Kairn T. Commissioning Tests of Radixact Synchrony Using Patient-Specific 3D-Printed Lung Phantom Inserts. *Cureus*. 2025 May 5;17(5):e83532. doi: 10.7759/cureus.83532. PMID: 40470410; PMCID: PMC12136657.

Hegi-Johnson F, Aly F, Bucknell N, **Kenny L**, Jabbour SK, Dilling TJ. In Reply to Luh *Int J Radiat Oncol Biol Phys*. 2025 Mar;15;121(4):1090-1091. doi: 10.1016/j.ijrobp.2024.11.110

Hindmarsh J, **Crowe S**, Johnson J, Sengupta C, **Walsh J**, Dieterich S, Booth J, Keall P. A dosimetric comparison of helical tomotherapy treatment delivery with real-time adaption and no motion correction. *Phys Imaging Radiat Oncol*. 2025 Mar 5;34:100741. doi: 10.1016/j.phro.2025.100741. PMID: 40129726; PMCID: PMC11931245.

Huang X, Leo P, Marshall M, Fink L, Ellis J, Hughes B, **Kenny L**, Vasani S, Punyadeera C. Tumour informed workflow to use ctDNA as a biomarker for risk of recurrence in head and neck cancer patients' post-treatment. *Authorea*. July 10, 2025.<https://doi.org/10.22541/au.175214185.57554698/v1>

Huang, X, Zhang X, Weeramange C, Leo P, **Hughes B**, Dolcetti R, Zeng B, Mazziere R, Hartel G, Ladwa R, Taheri R, Breik O, **Kenny L**, Vasani S, Punyadeera C. Development of a Circulating Tumour Cell Culture Model from Head and Neck Squamous Cell Carcinoma. DOI: 10.22541/au.174893062.20203367/v1

Hughes R, Corry J, Rischin D, Bressel M, **Kenny L**, Lehn B, Wishart L, Minslow LA, Frowen J. Swallowing and Communication Outcomes Post Chemoradiotherapy for Low-Risk Human Papillomavirus (HPV)-Associated Oropharyngeal Squamous Cell Carcinoma: A Substudy of TROG 12.01. *Head Neck*. 2025 Jul 15. doi: 10.1002/hed.28245. Online ahead of print. PMID: 40662470

Jangholi A, Basnayake B, Breik O, **Kenny L**, Vasani S, Dolcetti R, Punyadeera C. Potential clinical utility of small extracellular vesicles derived from head and neck tumours. *VIEW*. 2025, 20250081 <https://doi.org/10.1002/VIW.20250081>

Kairn T, Yu L, Crowe SB. A System for Verifying Radiation Therapy Treatments That Use Multiple Modes of Real-Time Motion Adaptation. *Cureus*. 2025 Apr 26;17(4):e83023. doi: 10.7759/cureus.83023. PMID: 40421340; PMCID: PMC12104770.

Parakh S, Gee H, Lim A, Vinod S, Wheeler C, Rooney B, Montgomery R, Harden S, Moore M, Lehman M, **Bettington C**, Moodie T, Barber J, Schmidt L, Dizon J, Leigh L, Oldmeadow C, Mitchell P, Hau E. Platinum and etoposide chemotherapy, durvalumab with thoracic radiotherapy in the first-line treatment of patients with extensive-stage small-cell lung cancer: CHEST-RT (TROG 20.01) Trial – protocol for a phase II study. *BMJ Open*. 2025 Jul 7;15(7): e101571. doi: 10.1136/bmjopen-2025-101571.

Retchford K, Donoghue V, Nath P, Youlden D, Dowthwaite S, **Chua, B** Statewide trends in oropharyngeal cancer management, p16 status, and patient outcomes in Queensland, 2012–2021 *Aust J Otolaryngol* 2025;8:53.2025 Dec 30 DOI [10.21037/ajo-25-27](https://doi.org/10.21037/ajo-25-27)

Journal Articles (RBWH staff or consumers in bold)

Rischin D, Porceddu S, Day F, Brungs DP, Christie H, Jackson JE, Stein BN, Su YB, Ladwa R, Adams G, Bowyer SE, Otty Z, Yamazaki N, Bossi P, Challapalli A, Hauschild A, Lim AM, Patel VA, Walker JL, De Liz Vassen Schurmann M, Queirolo P, Cañueto J, Ferreira da Silva FA, Stratigos A, Guminski A, **Lin C**, Damian F, Flatz L, Taylor AE, Carr DR, Harris S, Kirtbaya D, Quereux G, Rutkowski P, Basset-Seguin N, Khushalani NI, Robert C, Ju H, Joseph C, Bansal S, Chen CI, Seebach F, Yoo SY, Lowy I, Goncalves P, Fury MG; C-POST Trial Investigators. Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma. *N Engl J Med*. 2025 Aug 21;393(8):774-785. doi: 10.1056/NEJMoa2502449. Epub 2025 May 31. PMID: 40454639.

Vargas C, Carrello J, Bressel M, Sidhom M, **Lin C**, Vanneste B, Moon D, Appu S, Swaminath A, Ruben J, Pryor D, Higgs B, Davey R, Hardcastle N, Montgomery R, Siva S, Lourenço RA. Stereotactic Ablative Body Radiotherapy (SABR) versus Radiofrequency Ablation and cryoablation for Primary Renal Cell Carcinoma: an economic evaluation of the FASTRACK II trial. *Int J Radiat Oncol Biol Phys*. 2025 Jun 25:S0360-3016(25)03910-0. doi: 10.1016/j.ijrobp.2025.05.089. Epub ahead of print. PMID: 40578451.

Keynote or Plenary Lectures given in 2025

Date	Title
19/3/2025	Mackenzie P. Geriatric Oncology and Clinical Trials, TROG ASM 2025, Brisbane Australia
19/3/2025	McDowall R, Session chair Keynote Address TROG ASM 2025, Brisbane Australia
20/3/2025	Lin C. Session chair, Head and Neck and Skin Tumour Stream, TROG ASM 2025, Brisbane Australia

Oral Presentations (RBWH staff in bold) 2025

Peet S, Kairn T, Crowe S. Performing voxel-based secondary cancer risk calculations. RaySearch Australia and New Zealand User Meeting 2025, Brisbane Australia. 22/3/2025

Kairn T, Cassim N, Peet S, Crowe S. Commissioning RayStation beam models for extended-SSD total body irradiations treatments delivered using Varian iX, Edge and Truebeam linacs. RaySearch Australia and New Zealand User Meeting 2025, Brisbane Australia. 22/3/2025

Nag A. Evaluation of AI-reconstructed, low field, portable magnetic resonance imaging to contour brain anatomy for radiotherapy planning. Australian Society of Medical Imaging and Radiation Therapy (ASMIRT) 2025, Adelaide Australia 28-30/3/25

Wright G. Evaluation of surface guided radiation therapy versus tattoo-based positioning for treating tumours in the chest. Australian Society of Medical Imaging and Radiation Therapy (ASMIRT) 2025, Adelaide Australia 28-30/3/25

Choma K. Dose recalculation on cone beam CT – A decision making aid during radiation therapy treatment. RaySearch Australia and New Zealand User Meeting 2025, Brisbane Australia. 22/3/2025

Milsom B. A journey for a robust treatment solution for IMRT breast. RaySearch Australia and New Zealand User Meeting 2025, Brisbane Australia. 22/3/2025

Crowe SB, Luscombe J, Bennett J, Bennett C, Dawes J, Cassim N, Gordon S, Allen A, Blyth J, Kairn T. Creation of patient shielding for superficial radiotherapy using optical scanning and 3D printing. IUPESM World Congress on Medical Physics and Biomedical Engineering, Adelaide, Australia, 29/09/2025.

Kairn T, Cassim N, Charles P, Maxwell S, Livingstone A, Webb L, **Crowe S**. 3D printed face phantom for electron radiotherapy commissioning. IUPESM World Congress on Medical Physics and Biomedical Engineering, Adelaide, Australia, 29/9/2025.

O'Connor P, Crowe S, Charles P. Improved CBCT image quality used linearly mixed dual energy with iterative reconstructions. IUPESM World Congress on Medical Physics and Biomedical Engineering, Adelaide, Australia, 30/9/2025.

Crowe SB, Poroa T, Dawes J, Amarsee K, Kairn T. Thermoplastic polyurethane bolus: experience with a new low-cost 3D printer. IUPESM World Congress on Medical Physics and Biomedical Engineering, Adelaide, Australia, 2/10/2025.

Crowe SB, Walsh J, Bennett C, Bettington C, Chan P, Cooke S, O'Connor P, Peet S, Rattray G, Stewart K, Yu L, Kairn T. Processing real-time target tracking and adaptation data from the Radixact Synchrony system. IUPESM World Congress on Medical Physics and Biomedical Engineering, Adelaide, Australia, 2/10/2025.

Lancaster CM, Crowe SB, Alexander GW, Cheuk R, O'Connor P, Kairn T. Dual energy CT for brachytherapy catheter identification. IUPESM World Congress on Medical Physics and Biomedical Engineering, Adelaide, Australia, 1/10/2025.

Kairn T, Lancaster CM, Crowe SB. Characteristics of a 9 MeV electron beam for total skin electron radiotherapy evaluated in comparison to a 6 MeV **electron** beam. IUPESM World Congress on Medical Physics and Biomedical Engineering, Adelaide, Australia, 2/10/2025.

Oral Presentations (RBWH staff in bold) 2025

Kairn T, Bettington C, Chan P, Peet SC, Crowe SB. Characterisation of anatomical variations in the central nervous system to improve **safety** and precision of radiotherapy. IUPESM World Congress on Medical Physics and Biomedical Engineering, Adelaide, Australia, 1/10/2025.

Amarsee K, Crowe S, Peet S, Fontanarosa D, Hutmacher DW, Wille M-L. Improving accuracy in the use of radiotherapy in superficial disease. IUPESM World Congress on Medical Physics and Biomedical Engineering, Adelaide, Australia, 3

Lin C Adjuvant treatment **following** TORS: current treatment paradigm – Parallel Workshop, Brisbane Cancer Conference, Brisbane, Australia 27/11/2025

Chan P Prostate **Brachytherapy** Update. Brisbane Cancer Conference, Brisbane, Australia 27/11/2025

Medical Oncology

Research highlights



Dr David Wyld

Director of Medical Oncology

The Medical Oncology unit research group remains busy with a broad portfolio of clinical trials open to recruitment or in active follow up, including several new trials commencing recruitment in 2025. New study highlights include:

- **PaxPlus:** a Phase Ib collaboration with QIMR to evaluate the safety, tolerability, and clinical activity of combining paxalisib with standard therapy in patients with advanced breast cancer.
- **PSMACTION:** a phase II/III randomized study of combined novel targeted alpha therapies versus standard of care for patients with PSMApositive metastatic prostate cancer. This trial is one of a suite of studies which continues the collaboration with the Department of Nuclear Medicine as well as Herston Imaging Research Facility.
- **SUPER-ED:** a study looking at the introduction of a model of care with a dedicated cancer care coordinator for patients whose primary cancer is unknown.

There are ongoing strong collaborations between group members / RBWH and a number of Australasian collaborative clinical trials groups, including individuals having significant roles in these groups. In addition, multiple staff have active research collaborations with local groups in QIMR Berghofer, QUT and the UQ Centre for Clinical Research.

Over 30 manuscripts included medical oncology staff in 2025, including publications in *New England Journal of Medicine*, *The Lancet*, *Journal of Clinical Oncology*, and *European Journal of Cancer*.

Of note two clinical trials conducted at RBWH Cancer Care were presented at the annual American Society of Clinical Oncology meeting. CHALLENGE, a 3-year structured exercise program for colon cancer which resulted in significantly longer disease-free survival and findings consistent with longer overall survival, and DESQUAMATE, a trial using neoadjuvant pembrolizumab for locally advanced cutaneous squamous cell carcinoma leading to the potential to avoid surgery and radiotherapy for these patients.

The Integrated CANcer REsearch (I-CARE) Collaborative – Clinical Trials Team was awarded the Research Support Award at the 2025 Metro North Health Research Excellence Awards. This award recognises the team's outstanding contribution to oncology and haematology research across the Royal Brisbane and Women's Hospital, The Prince Charles Hospital, and North Lakes facilities. This achievement is a testament to the team's passion, expertise, and unwavering commitment to improving outcomes for people affected by cancer. It also reflects the collaborative spirit that defines Cancer Care Services

Special mention to Dr Zarnie Lwin who was recently awarded the academic title of Professor at The University of Queensland.

This prestigious recognition reflects Professor Lwin's outstanding leadership, her significant contributions to cancer care, and her sustained commitment to excellence in clinical practice, research, and education. Her work has had a profound impact across Cancer Care Services and the wider healthcare community, and this appointment acknowledges the depth and influence of her achievements.

Successful Research Higher Degree (e.g. MPhil or PhD) candidates in 2025

Name	Degree (e.g. MPhil or PhD)	Title	Month Completed	Affiliated University	Summary
Dr Habib Sadeghirad/ Dr Brett Hughes	PhD	The investigation of the tumour microenvironment in head and neck squamous cell carcinoma to identify predictive biomarkers of response to immunotherapy	2025	The University of Queensland	Head and neck cancer patients with recurrent and/or metastatic (R/M) disease often have a poor prognosis. Despite the promising outcomes shown by immune checkpoint blockades (ICBs), only a subset of patients is responsive. The literature points to the tumour microenvironment (TME) as the primary determinant of this phenomenon. Given this information, we aimed to examine the cellular and molecular features of HNSCC TMEs using patient tumour tissue samples before their immunotherapies.

Research Awards and Achievements 2025

Recipient (RBWH staff in bold)	Award	Event
Integrated Cancer Research (I-CARE) Collaborative – Clinical Trials	Research Support Award	Metro North Health (2025 Research Excellence Awards)
Professor Zarnie Lwin	Professorial Title Awarded to Dr Zarnie Lwin	Professor at the University of Queensland

Research Grants

Investigator Names (RBWH staff in bold)	RBWH Departments / Research Groups	Research Project Title	Granting Body	Total Awarded (whole all years)	Length of Awards in years and years active
Medical Oncology Clinical Trials Unit	CCS Medical Oncology	CCQ- Clinical Trials Data Management Grant. Medical Oncology	Cancer Council Queensland	\$70,000	1 year, 2025
Punyadeera C, Kenny L, Sriram S, Hughes B , Leo P, Papautsky I	CCS Medical Oncology	Multi-analyte liquid biopsy-based biomarkers for oropharyngeal cancer	NHMRC (National Health and Medical Research Council)	\$763,417	4 years, 2022-2025
Vanessa Beesley, Rachel Neale, Jane Turner, Patsy Yates, David Wyld , Raymond Chan, Louisa Gordon	CCS Medical Oncology	PRoCESS: Pancreatic cancer Relatives Counselling and Education Support Service trial. Assessing the effect of nurse-led counselling, compared with information alone, on participant-reported outcomes and use of medical services	NHMRC MRFF – Research Grant (APP1200326)	\$801,229	5 years, 2020-2025

Investigator Names (RBWH staff in bold)	RBWH Departments / Research Groups	Research Project Title	Granting Body	Total Awarded (whole all years)	Length of Awards in years and years active
J Zalcborg, K Sjoquist, N Tebbutt, D Yip, J Desai, T Price, L Lipton, C Diakos, S Ananda, C Kin Law, C Bishop, S Ackland, S Yip, R Morton, D Wyld , D Goldstein, J Mumford	CCS Medical Oncology	SSG XXII: International randomised phase III multicentre study of 3 v 5 years of adjuvant imatinib as treatment of patients with operable GIST with high risk for recurrence	NHMRC MRFF 2020 International Clinical Trial Collaborations	\$1,036,125	6 years, 2021-2026
Raymond Chan, Jon Emery, Michael Jefford, Nicolas Hart, Gillian Harvey, David Wyld (CI F), David Chan, Michelle Miller, Sanjeewa Kularatna, Lee Jones	CCS Medical Oncology	Implementing a Nurse-Enabled, Shared-Care Model to Address Unmet Needs of People with Neuroendocrine Tumours: the AUS-NET Trial	NHMRC 2021 MRFF Rare Cancers, Rare Diseases and Unmet Need	\$2,374,220	5 years, 2022-2026
K Fong, I Yang, H Marshall, R Bowman, R O'Rourke, P Valery, E Stone, R Manser, K Canfell, M Weber, G Garvey, S Lam, M Tammemagi, S Sabesan, Z Otty, F Brims, A McWilliams, B Page, J De Laat, S Hambleton, G Pratt, P Chan, M Windsor, R Naidoo, B Hughes , Z Lwin , K Hopcraft, M Toombs, P Fogart, P Tobias, B Bartholmai, F Maldonado, F Martignano, S Conticello, P Grogan, L Passmore, A Dent, G Olive, B Parris, H O'Farrell, K Chee	CCS Medical Oncology, CCS Radiation Oncology	Improving outcomes for people with and at risk of lung cancer.	Australian Cancer Research Foundation	\$2,000,000	4 years, 2022-2025

Investigator Names (RBWH staff in bold)	RBWH Departments / Research Groups	Research Project Title	Granting Body	Total Awarded (whole all years)	Length of Awards in years and years active
Penelope Schofield, Linda Mileskin, Anna Ugalde, Richard Tothill, Stephen Quinn, Hui-li Wong, Owen Prall, Catherine Mitchell, Nilmini Wickramasinghe, Clare Fedele, Colin Wood, Louisa Gordon, Christopher Steer, Rachel Wong, Mark Shackleton, Louise Nott, Shamsudheen Padinharakan, Zee Wan Wong, Anna Kuchel	CCS Medical Oncology	Solving Unknown Primary canCER Earlier Diagnosis (SUPER-ED): A stepped wedge cluster randomised controlled trial implementing a new model of care to support earlier diagnosis	MRFF (Medical Research Future Fund)	\$2,400,000	5 years, 2022-2026
Penny Webb, Nina Na, Susan Jordan, Karen Canfell, Jeffrey Goh , Yoland Antill, Ming Yin Lin, Paul Cohen, Felicia Roncolato, Megan Smith	CCS Medical Oncology	Investigate variation and inequality in care and survival to Improve outcomes for women with cervical, uterine, vaginal and vulvar cancer in Australia	Cancer Australia	\$599,307	4 years, 2023-2026
Sudha Rao, Corey Smith, Gunter Hartel, Maciej Trzaskowski, Zarnie Lwin , Jane Dahlstrom, Melissa Eastgate , Vladimir Andelkovic, Sayed Ali	CCS Medical Oncology	Epigenetic checkpoint blockade: a new approach to enhance immune-mediated control	NHMRC Ideas Grant 2022	\$1,280,076	5 years, 2023-2027
Vicki Whitehall, Eric Shifrut, Ann-Marie Patch, Catherine Bond, Bianca Nowlan, Jennifer Borowsky, Juan Dubrot, Matthew Burge , David Clark	CCS Medical Oncology	New Approaches for Sensitising Metastatic Colorectal Cancer to Immunotherapy	NHMRC Ideas Grant 2022	\$1,419,345	5 years, 2023-2027

Investigator Names (RBWH staff in bold)	RBWH Departments / Research Groups	Research Project Title	Granting Body	Total Awarded (whole all years)	Length of Awards in years and years active
R Jeffree, B Day, C Gedye, ES Koh, R Leonard, HW Sim, W Varikatt, D Hansen, D Cossio, R Harrup, H Gan, J Zalcbberg, T O'Brien, K Drummond, M Pinkham, R Ormsby, G Gomez, K Alexander, M Buckland, N Good, M Sachchithananthan, A Scott, J Whittle, D Ziegler, C Vajdic, W Lipworth, J Dickinson, L Quinn, J Aitken, Z Lwin , JHansford, A Yule, M Agar, G Kichenadasse, D Truran, G Francois, W Chin, B Kong, J Gabriel, A Lee, C Turner , S Evans, W Ng, R Sullivan, S Pitson, A Nguyen	CCS Medical Oncology	Australian Brain Cancer Research Infrastructure Grant: Supporting brain cancer care with an integrated network of platforms	MRFF (Medical Research Future Fund)	\$5,991,219	5 years, 2023-2027
Arutha Kulasinghe, Mark Adams, Gabrielle Belz, Dharmesh Bhuva, Charles Bidgood, Sophie Curio, Melissa Davis, Jennifer Gunter, Angela Huang, Brett Hughes , Ning Liu, Kenneth O'Byrne, Amelia Parker, Chin Wee Tan, Haitham Tuffaha	CCS Medical Oncology	METASPATIAL Study: Metabolic Spatial Analysis of Lung Cancer Study	MRFF (Medical Research Future Fund)	\$999,825	4 years, 2024-2028
Matthew Burge , David Wyld , David Pattison, Lorraine Chantrill, Michael Michael, Timothy Price, David Ransom, David Chan, Vicki Whitehall, Richard De Abreu Lourenço, Carrie-Anne Ng	CCS Medical Oncology	Cessation of Somatostatin Analogues after Peptide radionuclide Therapy in non-functioning mid-gut Neuroendocrine tumours (STOPNET)	MRFF (Medical Research Future Fund)	\$1,285,404	5 years, 2024-2029

Investigator Names (RBWH staff in bold)	RBWH Departments / Research Groups	Research Project Title	Granting Body	Total Awarded (whole all years)	Length of Awards in years and years active
Kim Alexander, Morgan Farley, Melissa Eastgate , Michael Smith, Claire Blake, Janine Deevy, Brigid Scanlon	CCS Medical Oncology	Co-design of a multidisciplinary wellness model of care to improve treatment outcomes for people receiving immunotherapy	Royal Brisbane & Women's Hospital	\$14,919	2 years, 2025-2026
Annette Lim, Fernando Rossello, Angela Pizzolla. Al Hughes .	CCS Medical Oncology	Defining immunotherapy response and resistance mechanisms in cutaneous squamous cell carcinoma	NHMRC Ideas Grant 2024	\$1,708,829	4 years, 2025 -2028

Current RBWH Department / Research Group Led Research Activity

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumers involvement	Number of RBWH Patients Recruited in 2025
Matthew Burge , Victoria Whitehall	David Wyld, Melissa Eastgate , Alison Hadley, Brett Hughes , Po-ling Inglis, Zarnie Lwin, Jeff Goh, Darshit Thaker , Bahram Forouzesh, Sudhakar Vemula, Elizabeth Ahern, Jennifer Borowsky	The Royal Brisbane and Prince Charles Hospital metastatic Colorectal Cancer database: A prospective observational cohort study examining clinical and molecular biomarkers	Involvement	0
Mark Nalder	Matthew Burge, David Wyld, Melissa Eastgate , Sarah Steinke	Pre-treatment dihydropyrimidine dehydrogenase (DPYD) genotyping to individualise fluoropyrimidine-based chemotherapy: An evaluation of clinical implementation in a tertiary cancer centre.	Involvement	0 Archived 8/4/2025
Melissa Eastgate	Michelle Wykes, Rebecca Faleiro, Deshapriya Karunarathne	INVITE: In vitro testing of a novel immunotherapy for advanced cancer	Involvement	7
Melissa Eastgate	Michele Teng, Bill Dougall, Margaret Cummings, Rosalind Jeffrey, Shu Lee, Anna Kuchel , Elizabeth Ahern	MISTY trial (Melanoma Immunotherapy Stratification and Treatment Sensitivity) Cutaneous Malignancies Group	Involvement	0
Melissa Eastgate	Sudha Rao, David Wyld, Kathy You , Robert McCuaig, Haidar Al-Saig, Harry Gasper, Jeff Goh, Brett Hughes, Po Inglis, Anna Kuchel, Zarnie Lwin, Darshit Thaker	Immunotherapy STARS (Stratifying Therapeutic Resistance and Sensitivity) - immunotherapy treatment cohort	Involvement	15
Chun Loo Gan	Haidar Al-Saig , Zi Long Chow, Ciara Conduit, Nattakorn Dhiantravan, Craig Gedy, Jeffrey Goh , Laurence Krieger, Anna Kuchel , Niara Oliveira, Shivanshan Pathmanathan, David Pattison, Steven Smith, Aneta Suder , Andrew Weickhardt, Yong Yeung	PREDICT-RCC: PREDICTing treatment response to first-line immunotherapy-based combinations with PSMA and FDG PET in advanced clear cell Renal Cell Carcinoma	Involvement	3
Brett Hughes	Elizabeth Ahern, Bill Dougall	Pharmacodynamics of pre-operative PD1 CheckPoint Blockade and Receptor Activator of NF-κB Ligand (RANKL) Inhibition in Non-Small Cell Lung Cancer (NSCLC) – a phase 1B/2 trial. POPCORN	Involvement	0 (in follow up)

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumers involvement	Number of RBWH Patients Recruited in 2025
Kyung You	Zarnie Lwin , Natasha Roberts	Multifactorial determinants that influence clinical trial participation by cancer patients in Australia.	Consultation	N/A
Brett Hughes	Cassie Turner	Outcomes for patients with radioactive iodine-refractory thyroid cancer treated within the Royal Brisbane and Women's Hospital	Consultation	N/A
Melissa Eastgate	Geoffrey Bryant, Mathew Burge , Darshit Thaker , David Wyld , Cameron Curley, Michele Grogan, Jemma Byth	Cancer patient reported outcomes: putting theory into practice	Involvement	297 In follow-up
Melissa Eastgate Elizabeth Ahern Anna Kuchel	Ailin Lepetier, Jason Madore	Multiplex immunofluorescence assessment of melanoma biopsies and response to immunotherapy	Consultation	N/A
Brett Hughes , Elizabeth Ahern	Martin Batstone, Bill Dougall	Immune Biomarker Evaluation in Oral Mucosal Squamous Cell Carcinoma: a prospective tissue collection	Consultation	N/A
Melissa Eastgate	Rosalind Jeffrey (Neurosurgery), Margaret Cummings (Pathology), Elizabeth Ahern, Anna Kuchel , Shu Lee (Medical Oncology Ipswich), Michael Colditz (Neurosurgery)	Clinicopathologic feature predicting survival after brain metastasectomy in melanoma	Consultation	N/A
Wessling C, Gavin N,	Russell E, Glynn T, Eastgate M , Hajkowicz K, Klages P, Leutenegger J, Sandler C, Clark B, Hutchinson E, Sutherland A,	A Randomised Controlled Trial exploring the administration of intravenous antibiotics and fluids via intravenous pole and pump versus portable CADD pump to improve mobility in patients diagnosed with cancer (The Active Trial)	Involvement	Not Available

Collaborative Research Activity Involving RBWH Department / Research Group

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited in 2025
Australasian Gastrointestinal Trials Group	Matthew Burge (Cancer Care Services)	STOPNET: A randomised study of cessation of somatostatin analogues after Peptide Receptor Radionuclide Therapy in Mid-Gut Neuroendocrine tumours	Involvement	8
Australasian Gastrointestinal Trials Group	Matthew Burge (Cancer Care Services)	A phase II trial to determine the efficacy of combining the HDAC inhibitor sodium valproate with EGFR monoclonal antibody (panitumumab or cetuximab) maintenance in the first-line treatment of patients with RAS wild type metastatic CRC (VADER study).	Involvement	2

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited in 2025
Australasian Gastrointestinal Trials Group	Matthew Burge (Cancer Care Services)	INTEGRATE II Randomised Phase III Double Blind Placebo Controlled Study of regorafenib in Refractory Advanced GastroOesophageal Cancer	Involvement	0 (in follow up)
Australasian Gastrointestinal Trials Group	Matthew Burge (Cancer Care Services)	ACTICCA-1 study: Adjuvant Chemotherapy with Gemcitabine and Cisplatin Compared to Observation After Curative Intent Resection of Cholangiocarcinoma and Muscle Invasive Gall Bladder Carcinoma (ACTICCA-1 Trial)	Involvement	0 (in follow up)
Australasian Gastrointestinal Trials Group	Matthew Burge (Cancer Care Services)	ASCEND: Randomized, phase 2 study of gemcitabine and nab-paclitaxel with CEND-1 or placebo in patients with untreated metastatic pancreatic ductal adenocarcinoma.	Involvement	0 (in follow up)
Australasian Gastrointestinal Trials Group intestinal Trials Group	Melissa Eastgate (Cancer Care Services)	ASCOLT: Aspirin for Dukes C and high-risk Dukes B Colorectal Cancers: An international, multi-centre, double blind, randomised placebo controlled Phase III trial (AGITG)	Involvement	0 (in follow up) Archived 31/7/2025
Australasian Gastrointestinal Trials Group	Matthew Burge (Cancer Care Services)	MONARCC: A randomised phase 2 study of Panitumumab monotherapy versus fluoropyrimidine and bevacizumab as first line therapy for RAS wild type metastatic colorectal cancer	Involvement	0 (in follow up)
Breast Cancer Trials	Po-Ling Inglis (Cancer Care Services)	BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre, International Phase 3 Study to determine the Preventive Effect of Denosumab on Breast Cancer in Women carrying a BRCA1 Germline Mutation	Involvement	1 (in follow up) Archived 11/11/2025
Breast Cancer Trials	Po-Ling Inglis (Cancer Care Services)	FINER: A double-blind placebo controlled randomized Phase III trial of fulvestrant and ipatasertib as treatment for advanced HER-2 negative and estrogen receptor positive (ER+) breast cancer following progression on first line CDK 4/6 inhibitor and aromatase inhibitor	Involvement	0 (in follow up)

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited in 2025
Australia New Zealand Breast Cancer Trials Group	Michelle Nottage (Cancer Care Services)	PALLAS: PALbociclib CoLLaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer	Involvement	0 (in follow up)
Australia New Zealand Breast Cancer Trials Group	Po-Ling Inglis (Cancer Care Services)	Penelope B: Phase III study evaluating palbociclib (PD-0332991), a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor in patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy	Involvement	0 Archived 4/4/2025
Australia New Zealand Breast Cancer Trials Group/Breast International Group	Michelle Nottage (Cancer Care Services)	TEXT-Bone: A substudy of the TEXT trial to evaluate serial bone markers for bone remodelling, serial growth factors, and bone mineral density	Involvement	0 Archived 7/4/2025
Australia New Zealand Breast Cancer Trials Group/Breast International Group	Michelle Nottage (Cancer Care Services)	TEXT: A Phase III Trial Evaluating the Role of Exemestane plus GnRH analogue as Adjuvant Therapy for premenopausal women with endocrine responsive breast cancer	Involvement	0 Archived 7/4/2025
Australia New Zealand Gynaecological Oncology Group	Jeffrey Goh (Cancer Care Services)	ADELE: Adjuvant Tislelizumab plus chemotherapy after post-operative pelvic chemoradiation in high-risk endometrial cancer	Involvement	0
Australia New Zealand Gynaecological Oncology Group	Jeffrey Goh (Cancer Care Services)	EPOCH: Eribulin and Pembrolizumab in Ovarian/uterine Carcinosarcoma and sarcoma: A Phase 2 study of the single agent microtubule inhibitor, Eribulin or of Eribulin in combination with the PD-1 inhibitor, Pembrolizumab, in relapsed ovarian/fallopian tube carcinosarcoma (OCS), uterine carcinosarcoma (UCS), angiosarcoma and liposarcoma	Involvement	0 (in follow up)

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited in 2025
Australia New Zealand Gynaecological Oncology Group	Jeffrey Goh (Cancer Care Services)	Phase III Double-Blind Randomized Placebo Controlled Trial of Atezolizumab in Combination with Paclitaxel and Carboplatin in Women with Advanced/Recurrent Endometrial Cancer (Atezolizumab Trial in Endometrial cancer - AtTEnd)	Involvement	
Australia New Zealand Gynaecological Oncology Group	Jeffrey Goh (Cancer Care Services)	PARAGON-II: Phase II basket study of an ARomatase inhibitor plus PI3KCA inhibitor or CDK4/6 inhibitor in women with hormone receptor positive recurrent/metastatic Gynaecological Neoplasms	Involvement	
Australia New Zealand Gynaecological Oncology Group	Jeffrey Goh (Cancer Care Services)	ICON 9: to assess the efficacy, safety and tolerability of maintenance cediranib in combination with olaparib therapy compared to single agent cediranib maintenance in women with relapsed platinum sensitive ovarian, fallopian tube or primary peritoneal cancer	Involvement	
Australia and New Zealand Melanoma Trials Group	Melissa Eastgate (Cancer Care Services)	STOP-GAP: A randomised phase III study of duration of Anti-PD-1 therapy in metastatic melanoma	Involvement	
Australia New Zealand Urogenital and Prostate Cancer Trials Group	David Wyld (Cancer Care Services)	BEP: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for participants with intermediate and poor-risk advanced germ cell tumours	Involvement	
Australia New Zealand Urogenital and Prostate Cancer Trials Group	Anna Kuchel (Cancer Care Services)	CLIMATE: Assessing the Clinical utility of miR-371a-3p as a marker of residual disease in Clinical Stage 1 Testicular Germ Cell Tumour, following orchidectomy.	Involvement	
Australia New Zealand Urogenital and Prostate Cancer Trials Group	Jeffrey Goh (Cancer Care Services)	EVOLUTION: Phase II Study of Radionuclide ¹⁷⁷ Lu-PSMA Therapy versus ¹⁷⁷ Lu-PSMA in Combination with Ipilimumab and Nivolumab for Men with Metastatic Castration Resistant Prostate Cancer (mCRPC)	Involvement	0 (in follow up)
Australia New Zealand Urogenital and Prostate Cancer Trials Group	Aneta Suder (Cancer Care Services)	UpFront PSMA: A Randomised Phase 2 Study of Sequential ¹⁷⁷ Lu-PSMA617 and Docetaxel versus Docetaxel in Metastatic Hormone-Naïve Prostate Cancer	Involvement	0 (in follow up)

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited in 2025
Australia New Zealand Urogenital and Prostate Cancer Trials Group	Aneta Suder (Cancer Care Services)	ENZAMET Trial: A randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer	Involvement	0 (in follow up)
Australia New Zealand Urogenital and Prostate Cancer Trials Group	Jeffrey Goh (Cancer Care Services)	ENZA-p: A phase 2 open label randomised trial of enzalutamide versus enzalutamide+ Lu PSMA 617, in the early mCRPC setting prior to chemotherapy (stratified for hormone sensitive chemo) in men at high risk of early treatment failure on enzalutamide alone. (ANZUP)	Involvement	0 (in follow up)
Australia New Zealand Urogenital and Prostate Cancer Trials Group	Jeffrey Goh (Cancer Care Services)	KEYPAD: Proposed phase 2 trial of pembrolizumab and denosumab in advanced clear-cell renal cell carcinoma (ccRCC) progressing after a VEGF-TKI	Involvement	0 (in follow up)
Australia New Zealand Urogenital and Prostate Cancer Trials Group	Jeffrey Goh (Cancer Care Services)	UNICAB: A phase II trial of single agent cabozantinib in patients with locally advanced or metastatic non-clear cell renal cell carcinoma post immunotherapy or who are unsuitable for immunotherapy	Involvement	0 Archived 20/11/2025
Australian Genomic Cancer Medicine Centre, University of Sydney	Brett Hughes (Cancer Care Services)	MoST 08: Molecular Screening and Therapeutics (MoST) Program Substudies 19-20 and 35-36: Single arm, open label, signal seeking, phase IIa trial of the activity of Trastuzumab emtansine (T-DM1) in patients with tumours harbouring HER2 amplifications or mutations	Involvement	0 (in follow up)
Australian Genomic Cancer Medicine Centre, University of Sydney	Brett Hughes (Cancer Care Services)	MoST 12: Molecular Screening and Therapeutics (MoST) Program and ASPIRATION subprogram substudies 27 - 30: Single arm, open label, phase II trial of the activity of vemurafenib and cobimetinib in patients with advanced tumours harbouring BRAF V600 mutations detected by comprehensive genomic profiling.	Involvement	0 (in follow up)

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited in 2025
Australian Genomic Cancer Medicine Centre, University of Sydney	Brett Hughes (Cancer Care Services)	MoST Aspiration Framework: An observational cohort study to assess the clinical impact of comprehensive genomic profiling in metastatic lung cancer patients. A subprogram within the MoST Framework protocol	Involvement	0 (in follow up)
BioGrid Australia	Jeffrey Goh (Cancer Care Services)	ePAD: Analyzing Treatment Patterns and Outcomes from Real-World Patients with Castrate-Resistant Prostate Cancer (CRPC)	Involvement	0
BioGrid Australia	Matthew Burge (Cancer Care Services)	TRACC: Study of Clinical Outcomes and Analysis of Bevacizumab use in Metastatic Colorectal Cancer	Involvement	0
Canadian Cancer Trials Group	Matthew Burge (Cancer Care Services)	CHALLENGE: A Phase III study of the impact of a Physical Activity program on Disease-Free Survival in patients with high risk Stage II or Stage III Colon Cancer: a randomised controlled trial	Involvement	0 (in follow up)
Cooperative Trials Group for Neuro-oncology	Zarnie Lwin (Cancer Care Services)	LUMOS2: Low and Anaplastic Grade Glioma Umbrella Study of Molecular Guided Therapies: A phase 2, multi-centre, open-label, biomarker-directed, umbrella, clinical trial for recurrent IDH mutant, grade 2/3 glioma.	Involvement	1
Cooperative Trials Group for Neuro-oncology	Zarnie Lwin (Cancer Care Services)	MAGMA Trial: The Multi-Arm Glioblastoma Australasia Trial	Involvement	0 (in follow up)
Edith Cowan University	Matthew Burge (Cancer Care Services)	EXPAN: Exercise medicine as chemotherapy adjunct: multicomponent program in pancreatic cancer patients receiving neoadjuvant therapy	Involvement	0
Flinders University	Michelle Nottage (Cancer Care Services)	Finding My Way – Advanced: Can a web-based psychosocial intervention improve mental quality of life for women with metastatic breast cancer?	Involvement	0 (in follow up)
Flinders University	David Wyld (Cancer Care Services)	Implementing a Nurse-Enabled, Shared-Care Model to Address Unmet Needs of People with Neuroendocrine Tumours – a randomised-controlled type II hybrid effectiveness-implementation trial (the AUS-NET trial)	Involvement	19
Mater Misericordiae Ltd and Mater Research Ltd	David Wyld (Cancer Care Services)	ZOVa: A phase 1 PET-CT study of 89Zr-hu/mo-10D7 in patients with advanced epithelial Ovarian Cancer	Involvement	5

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited in 2025
Melanoma and Skin Cancer Trials Limited	David Wyld (Cancer Care Services)	GoTHAM: A Merkel Cell Carcinoma (MCC) study testing the immunotherapy drug Avelumab in combination with either radionuclide therapy or external beam radiotherapy	Involvement	0
Melanoma and Skin Cancer Trials Limited	Melissa Eastgate (Cancer Care Services)	I-MAT: - A randomised, placebo-controlled, phase II trial of adjuvant Avelumab in patients with stage I-III Merkel cell carcinoma	Involvement	0 (in follow up)
Metro South HHS	Brett Hughes (Cancer Care Services)	DESQUAMATE: A phase 2 study of de-escalation in resectable, locally advanced cutaneous squamous cell carcinoma with the use of neoadjuvant Pembrolizumab.	Involvement	1
NeuroEndocrine Cancer Australia	David Wyld (Cancer Care Services)	An Observational, Multi-centre, Non-Interventional Programme to Register Patients Diagnosed with Neuroendocrine Neoplasms (NENs) and Monitor their Patterns of Care in Australian Hospitals. PLANET Registry	Involvement	0
Olivia Newton-John Cancer Research Institute	Chun Loo Gan (Cancer Care Services)	PIRC PSMA PET: 68Ga-PSMA PET as a potential Imaging biomarker post tyrosine kinase inhibition of metastatic clear cell Renal cell Carcinoma	Involvement	0 (in follow-up)
Peter MacCallum Cancer Centre	Brett Hughes (Cancer Care Services)	AURORA: AUstralian Registry Of thoRacic cancers	Involvement	1
Peter MacCallum Institute	Anna Kuchel (Cancer Care Services)	Solving Unknown Primary canCER Earlier Diagnosis (SUPER-ED): A stepped wedge cluster randomised controlled trial implementing a Model of Care to support earlier diagnosis	Involvement	4
Peter MacCallum Cancer Centre	David Wyld (Cancer Care Services)	NET SANGUIS: The potential role of circulating DNA in the management of neuroendocrine tumours.	Involvement	0 Archived 21/5/2025
Peter MacCallum Institute	Anna Kuchel (Cancer Care Services)	SUPER-NEXT: Complete Whole Genome Sequencing for Cancer of Unknown Primary	Involvement	0 (in follow up)
Southern Adelaide Local Health Network Incorporated	Matthew Burge (Cancer Care Services)	NEO-CREATE: Neoadjuvant Immune-Chemo-Radiotherapy in operable oEsophageal and gastro-oesophageal junction cancers with Carboplatin Paclitaxel Radiotherapy and Avelumab - a Trial assessing feasibility and preliminary Efficacy	Involvement	0 (in follow up)

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited in 2025
Thoracic Oncology Group Australia	Brett Hughes (Cancer Care Services)	OCEANIC: A Phase II, Open-label, Multi-centre Clinical Trial of Osimertinib with or Without Adjuvant Chemotherapy Guided by Tumour NGS Co-mutation Status and ctDNA Detection in Patients with Stage IIA-IIIa EGFR-Mutant Non-Small Cell Lung Cancer Following Complete Surgical Resection	Involvement	1
Thoracic Oncology Group Australia	Brett Hughes (Cancer Care Services)	SHERLOCK: Phase 2 trial of sotorasib in combination with carboplatin-pemetrexed and bevacizumab-biosimilar as first line treatment for advanced non-squamous non-small cell lung cancer with KRAS G12C mutation	Involvement	0 (in follow up)
Thoracic Oncology Group Australia	Brett Hughes (Cancer Care Services)	BR.31: A Phase III prospective double-blind placebo controlled randomized study of adjuvant MEDI4736 in completely resected non-small cell lung cancer.	Involvement	0 (in follow up)
Thoracic Oncology Group Australia	Brett Hughes (Cancer Care Services)	BR.34: A randomized trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with high-risk, metastatic (stage IV) squamous or non-squamous non-small cell lung cancer (NSCLC).	Involvement	0 (in follow up)
Thoracic Oncology Group Australia	Brett Hughes (Cancer Care Services)	DREAM3R: DuRvalumab (MEDI4736) with chemotherapy as first line treatment in advanced pleural Mesothelioma - A phase 3 Randomised trial	Involvement	0 (in follow up)
University of Newcastle	Matthew Burge (Cancer Care Services)	GeneScreen: DPYD Genotype-guided dose Personalisation for Fluoropyrimidine prescribing in Cancer	Involvement	127
Walter and Eliza Hall Institute	Chun Loo Gan (Cancer Care Services)	Bladder and Urothelial Cancer Data and Biobank	Involvement	0
Walter and Eliza Hall Institute	Anna Kuchel (Cancer Care Services)	iTestis: Bioinformatics for Testis Cancer	Involvement	3
Walter and Eliza Hall Institute	Chun Loo Gan (Cancer Care Services)	KRAB: Kidney cancer Australian registry and Biobank.	Involvement	0
Walter and Eliza Hall Institute	Matthew Burge (Cancer Care Services)	PURPLE: Pancreatic cancer: Understanding Routine Practice and Lifting End results; A Prospective Pancreatic Cancer clinical registry	Involvement	0
Walter and Eliza Hall Institute	Michelle Nottage (Cancer Care Services)	TABITHA: Study of the clinical outcomes and analysis of anti-HER2 therapy in treatment of metastatic HER2 positive breast cancer	Involvement	3

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited in 2025
Walter and Eliza Hall Institute	Michelle Nottage (Cancer Care Services)	ARORA: Advanced Hormone Receptor Positive Breast Cancer Registry in Australia	Involvement	0 (in follow up)
Walter and Eliza Hall Institute	Matthew Burge (Cancer Care Services)	Evaluation of temporal dynamics of RAS Mutation emergence in Cell Free DNA (cfDNA) in response to first-line cetuximab anti-EGFR therapy in Patients with Metastatic Colorectal Cancer	Involvement	0 (in follow up)
Walter and Eliza Hall Institute	Matthew Burge (Cancer Care Services)	DYNAMIC: Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Stage II Colon Cancer	Involvement	0 (in follow up)
Walter and Eliza Hall Institute	Matthew Burge (Cancer Care Services)	DYNAMIC III: Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colon Cancer: A Multicentre Phase II/III Randomised Controlled Study (AGITG, WEHI)	Involvement	0 (in follow up)
Walter and Eliza Hall Institute	Matthew Burge (Cancer Care Services)	DYNAMIC-Pancreas: Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Early-Stage Pancreatic Cancer: A Multicentre Randomised Study (WEHI, AGITG)	Involvement	0 (in follow up)
AbbVie Pty Ltd	Anna Kuchel (Cancer Care Services)	IMGN853-0425: A randomized Phase 2, open-label study of mirvetuximab soravtansine in patients with platinum-resistant advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression testing 2 schedules of administration for dose optimization, with a separate cohort to determine starting dose in patients with moderate hepatic impairment.	Involvement	0
AdvanCell Isotopes Ltd	David Wyld (Cancer Care Services)	TheraPb: Phase I Biodistribution and Dosimetry Study of [203Pb]Pb-ADVC001 in Metastatic Prostate Adenocarcinoma	Involvement	5
Alpha-9 Theranostics	Melissa Eastgate (Cancer Care Services)	Alpha-9: A Multicentre, Phase 1 Study Investigating the Safety, Tumor Uptake, Biodistribution, and Dosimetry of 68Ga-A9T-3202 in Participants with Metastatic Melanoma	Involvement	1
ALX Oncology	Brett Hughes (Cancer Care Services)	ASPEN-03: A Phase 2 Study of ALX148 in Combination with Pembrolizumab in Patients with Advanced Head and Neck Squamous Cell Carcinoma	Involvement	0 (in follow up)

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited in 2025
ALX Oncology	Brett Hughes (Cancer Care Services)	ASPEN-04: A Phase 2 Study of ALX148 in Combination with Pembrolizumab and Chemotherapy in Patients with Advanced Head and Neck Squamous Cell Carcinoma	Involvement	0 (in follow up)
Astellas	Matthew Burge (Cancer Care Services)	Phase 3, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma study.	Involvement	0 (awaiting OTR)
AstraZeneca	Melissa Eastgate (Cancer Care Services)	EMERALD-1: A Phase III, Randomized, Double-blind, Placebo-controlled, Multicentre Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma	Involvement	0 (in follow up)
AstraZeneca	Brett Hughes (Cancer Care Services)	eOLVE-Meso: A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed Versus Platinum plus Pemetrexed or Nivolumab plus Ipilimumab in Participants with Unresectable Pleural Mesothelioma	Involvement	2
AstraZeneca	Brett Hughes (Cancer Care Services)	Flaura 2: A Phase III, Open-label, Randomized Study of Osimertinib with or without Platinum Plus Pemetrexed Chemotherapy, as First-line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer	Involvement	0 (in follow up)
BMS (Bristol-Myers Squibb)	Brett Hughes (Cancer Care Services)	CA224-1093 NSCLC: A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and with Tumor Cell PD-L1 Expression = 1%	Involvement	1

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited in 2025
BMS (Bristol-Myers Squibb)	Po-Ling Inglis (Cancer Care Services)	IZABRIGHT-BREAST01: A Randomized, open-label, phase 3 study of BL-B01D1 (BMS-986507) versus treatment of physician's choice in patients with previously untreated, locally advanced, recurrent inoperable or metastatic Triple-Negative Breast Cancer (TNBC) who are not candidates for approved anti-PD1/PD-L1 with chemotherapy combination.	Involvement	0 (awaiting OTR)
BMS (Bristol-Myers Squibb)	Chun Loo Gan (Cancer Care Services)	A Phase 1/1b Open-label Study of BMS-986488 as Monotherapy and Combination Therapy in Participants with Advanced Malignant Tumors	Involvement	0 (awaiting OTR)
BMS (Bristol-Myers Squibb)	Matthew Burge (Cancer Care Services)	Phase 2/3 study with BMS-986504, Gemcitabine & Nab-Paclitaxel in participants with untreated Metastatic PDAC with homozygous MTAP Deletion	Involvement	0 (awaiting OTR)
BMS (Bristol-Myers Squibb)	Melissa Eastgate (Cancer Care Services)	CA209-76K: A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy with Nivolumab versus Placebo after Complete Resection of Stage IIB/C Melanoma	Involvement	0 (in follow up)
BMS (Bristol-Myers Squibb)	Jeffrey Goh (Cancer Care Services)	CA209-9ER: A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib or Nivolumab and Ipilimumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma	Involvement	0 (in follow up) Archived 21/5/2025
Chimerix	Zarnie Lwin (Cancer Care Services)	The ACTION Study: ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study	Involvement	1
Coherus BioSciences	Melissa Eastgate (Cancer Care Services)	CHS-388-202: A Randomized Phase 2 Study of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants with Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma	Involvement	0

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited in 2025
Exelixis	Brett Hughes (Cancer Care Services)	Exelixis Thyroid XL184-401: A Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients	Involvement	0 (in follow up)
Gilead Sciences Inc.	Po-Ling Inglis (Cancer Care Services)	ASCENT-07: A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients with Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH-]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy	Involvement	0 (in follow up)
Gilead Sciences Inc.	Brett Hughes (Cancer Care Services)	EVOKE-SCLC-04: A Global, Multicenter, Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Standard of Care in Participants with Previously Treated Extensive Stage Small Cell Lung Cancer	Involvement	1
Global Coalition for Adaptive Research (GCAR)	Zarnie Lwin (Cancer Care Services)	GBM AGILE: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent Glioblastoma	Involvement	2
HUYA Bioscience International	Melissa Eastgate (Cancer Care Services)	HUYA Melanoma: A Multicenter, Randomized, Double-Blind Phase 3 Study of HBI-8000 Combined with Nivolumab versus Placebo with Nivolumab in Patients with Unresectable or Metastatic Melanoma Not Previously Treated with PD-1 or PD-L1 Inhibitors	Involvement	0 (in follow up)
LOXO Oncology	Brett Hughes (Cancer Care Services)	LOXO – EAP: A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged During Transfection (RET) Activation	Involvement	0 (in follow up)
MSD (Merck Sharp & Dohme Corp.)	Jeffrey Goh (Cancer Care Services)	KEYFORM-010: A Multicenter, Randomized, Double-Blind, Phase 2, Basket Study of MK-4280A, a Coformulation of Favezelimab (MK-4280) with Pembrolizumab (MK-3475) in Selected Solid Tumors	Involvement	0 (in follow up)

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited in 2025
MSD (Merck Sharp & Dohme Corp.)	Jeffrey Goh (Cancer Care Services)	KEYMAKER-U03: A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants with RCC	Involvement	0 (in follow up)
MSD (Merck Sharp & Dohme Corp.)	Chun Loo Gan (Cancer Care Services)	KEYMAKER-U04B: A Phase 1/2 Randomized, Umbrella Study to Evaluate the Safety and Efficacy of Pembrolizumab Plus Enfortumab Vedotin (EV) in Combination with Investigational Agents Versus Pembrolizumab Plus EV, as First-Line Treatment for Participants With Advanced Urothelial Carcinoma (KEYMAKER-U04) Substudy 04B	Involvement	0 (in follow up)
MSD (Merck Sharp & Dohme Corp.)	Matthew Burge (Cancer Care Services)	KEYNOTE-158: A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors	Involvement	0 (in follow up)
MSD (Merck Sharp & Dohme Corp.)	Jeffrey Goh (Cancer Care Services)	KEYNOTE-365: Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC)	Involvement	0
MSD (Merck Sharp & Dohme Corp.)	Po-Ling Inglis (Cancer Care Services)	KEYNOTE-522: A Phase 3, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)	Involvement	0 (in follow up)
MSD (Merck Sharp & Dohme Corp.)	Brett Hughes (Cancer Care Services)	KEYNOTE-587: A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab	Involvement	0
MSD (Merck Sharp & Dohme Corp.)	Brett Hughes (Cancer Care Services)	KEYNOTE-689: A Phase 3, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination with Standard of Care as Adjuvant Therapy for Stage 3-IVB Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)	Involvement	0 (in follow up)

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited in 2025
MSD (Merck Sharp & Dohme Corp.)	Jeffrey Goh (Cancer Care Services)	KEYNOTE-A18: A randomised, Phase 3, double-blind study of chemoradiotherapy with or without pembrolizumab for the treatment of high-risk, locally advanced cervical cancer.	Involvement	0 (in follow up)
MSD (Merck Sharp & Dohme Corp.)	Jeffrey Goh (Cancer Care Services)	KEYNOTE-B61: A Phase 2, Open Label, Study of Pembrolizumab + Lenvatinib for 1L nccRCC (advanced or metastatic nccRCC)	Involvement	0 (in follow up)
MSD (Merck Sharp & Dohme Corp.)	Jeffrey Goh (Cancer Care Services)	KEYNOTE-C93: A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab vs. Platinum Doublet Chemotherapy in Participants with Mismatch Repair Deficient (dMMR) for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma	Involvement	0 (in follow up)
MSD (Merck Sharp & Dohme Corp.)	Melissa Eastgate (Cancer Care Services)	KEYVIBE-010: A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab with Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma	Involvement	0 (in follow up)
MSD (Merck Sharp & Dohme Corp.)	Zarnie Lwin (Cancer Care Services)	LEAP-005: A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumours	Involvement	0 (in follow up)
MSD (Merck Sharp & Dohme Corp.)	Matthew Burge (Cancer Care Services)	LEAP-015: Pembrolizumab plus Lenvatinib plus Chemotherapy for the treatment of advanced/metastatic HER2 negative gastric/gastroesophageal junction adenocarcinoma	Involvement	0 (in follow up)
MSD (Merck Sharp & Dohme Corp.)	Jeffrey Goh (Cancer Care Services)	MK-2870-005: A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice in Participants with Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy	Involvement	1

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited in 2025
MSD (Merck Sharp & Dohme Corp.)	Michelle Nottage (Cancer Care Services)	MK-2870-012: A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice (TPC) in Participants with Triple-Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) at Surgery	Involvement	2
MSD (Merck Sharp & Dohme Corp.)	Brett Hughes (Cancer Care Services)	MK-2870-019: A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab with or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery	Involvement	2
MSD (Merck Sharp & Dohme Corp.)	Jeffrey Goh (Cancer Care Services)	MK-2870-020: A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice as Second-Line or Third-Line Treatment for Participants with Recurrent or Metastatic Cervical Cancer	Involvement	1
MSD (Merck Sharp & Dohme Corp.)	Jeffrey Goh (Cancer Care Services)	MK-2870-033: A Phase 3 Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan in Combination with Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants with Mismatch Repair Proficient Endometrial Cancer (TroFuse-033)	Involvement	0
MSD (Merck Sharp & Dohme Corp.)	Matthew Burge (Cancer Care Services)	MK-4280A-007: A Phase 3 study of MK-4280A [co-formulated favezelimab (MK-4280) plus pembrolizumab (MK-3475)] Versus Standard of Care in Previously Treated Metastatic PD-L1 positive Colorectal Cancer	Involvement	0 (in follow up) Archived 20/11/2025

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited in 2025
MSD (Merck Sharp & Dohme Corp.)	Jeffrey Goh (Cancer Care Services)	MK-5684-004: A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed on or After Prior Treatment with One Next-generation Hormonal Agent (NHA)	Involvement	3
MSD (Merck Sharp & Dohme Corp.)	Jeffrey Goh (Cancer Care Services)	MK-6482-022: A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy	Involvement	0 (in follow up)
MSD (Merck Sharp & Dohme Corp.)	Matthew Burge (Cancer Care Services)	MK-9999-02A: A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination with Other Anticancer Agents in Gastrointestinal Cancers	Involvement	2 (in follow up)
MSD (Merck Sharp & Dohme Corp.)	Jeffrey Goh (Cancer Care Services)	V940-004: Phase 2, Randomized, Double-blind, Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Participants with Renal Cell Carcinoma	Involvement	0 (in follow up)
MSD (Merck Sharp & Dohme Corp.)	Brett Hughes (Cancer Care Services)	V940-007: A Phase 2/3, adaptive, randomized, open-label, clinical study to evaluate neoadjuvant and adjuvant V940 (mRNA-4157) in combination with pembrolizumab (MK-3475) versus standard of care, and pembrolizumab monotherapy in participants with resectable locally advanced cutaneous squamous cell carcinoma (LA cSCC)	Involvement	0 (in follow up)
Novartis	Jeffrey Goh (Cancer Care Services)	PSMACTION: A phase II/III, open-label, international, multicentre, randomized study of AAA817 versus standard of care in the treatment of adult participants with PSMApositive metastatic castration-resistant prostate cancer who progressed on or after [177Lu]Lu-PSMA targeted therapy. (CAAA817A12201)	Involvement	3

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited in 2025
Pfizer Pharmaceuticals	Brett Hughes (Cancer Care Services)	B9991005: Avelumab Master Protocol: An open-label continuation study for participants continuing from Pfizer sponsored avelumab clinical studies. Sub-Study title: An open-label study for continued treatment access for participants from the B9991005 avelumab study.	Involvement	0 (in follow up)
Pfizer Pharmaceuticals	Matthew Burge (Cancer Care Services)	BREAKWATER (C4221015): An open-label, multicentre, randomized phase 3 study of first-line Encorafenib plus Cetuximab with or without chemotherapy versus standard of care therapy with a safety lead-in of Encorafenib and Cetuximab plus chemotherapy in participants with metastatic BRAF V600E-mutant colorectal cancer.	Involvement	0 (in follow up)
Queensland Institute of Medical Research Berghofer Medical Research Institute	Michelle Nottage (Cancer Care Services)	PaxPlus-ABC (KZA-0084-ABC001): A phase 1b, multi-centre, open-label, randomized study to evaluate the safety, tolerability, and clinical activity of combining paxalisib with olaparib or pembrolizumab/chemotherapy in patients with advanced breast cancer	Involvement	1
Regeneron	Brett Hughes (Cancer Care Services)	R2810-ONC-1901: A Phase II Study of Neoadjuvant Cemiplimab for Stage II-IV (M0) Cutaneous Squamous Cell Carcinoma (CSCC).	Involvement	0 (in follow up)
Servier Affaires Medicales	Melissa Eastgate (Cancer Care Services)	ProVIDHe: An Open-Label Early Access Phase 3b Study of Ivosidenib in Patients with a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma	Involvement	0 (in follow up)
Queensland University of Technology	Jeffrey Goh (Cancer Care Services), Aneta Suder (Cancer Care Services), Natasha Roberts (STARS)	IRONMAN: International registry for men with advanced prostate cancer	Involvement	0
Patsy Yates (Palliative Care)	David Wyld (Cancer Care Services), Kimberly Alexander, Christine Miaskowski, Raymond Chan, Alexandra McCarthy, Steven McPhail, Helen Skerman	A sequential multiple assignment randomised trial (SMART) of nursing interventions to reduce pain associated with chemotherapy induced peripheral neuropathy	Involvement	Not available
Teresa Brown (Nutrition and Dietetics)	Judy Bauer (University of Queensland), Brett Hughes (Cancer Care Services) Elizabeth Ahern	"Sarcopenia in HNSCC patients undergoing definitive concurrent CRT and associations with clinical outcomes"	Consultation	Not available

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited in 2025
Connor O'Leary, (PAH)	Ken O'Byrne (PAH), Derek Richard (QUT), Elizabeth McCaffrey (PAH), Mark Adams (QUT), Arutha Kulasinghe (QUT), Brett Hughes (Cancer Care Services), Rahul Ladwah (PAH), Josh Burges (QUT)	Identification and clinical validation of potential cancer biomarkers	Consultation	Not available

Research Publications

Authors

Investigator	ORCID ID
David Wyld	https://orcid.org/0000-0001-9523-4333
Zarnie Lwin	https://orcid.org/0000-0003-1064-8444
Haidar Al-Saig	
Matthew Burge	https://orcid.org/0000-0003-2562-7806
Melissa Eastgate	https://orcid.org/0000-0002-7560-5026
Chun Loo Gan	https://orcid.org/0000-0003-2576-9310
Jeffrey Goh	https://orcid.org/0000-0003-3103-146X
Brett Hughes	https://orcid.org/0000-0002-1811-0537
Po-Ling Inglis	
Tivya Kulasegaran	https://orcid.org/0009-0002-7873-9350
Anna Kuchel	https://orcid.org/0000-0001-8580-2974
Mark Nalder	https://orcid.org/0000-0002-9310-1489
Michelle Nottage	https://orcid.org/0000-0002-1620-1961
Aneta Suder	
Darshit Thaker	https://orcid.org/0000-0002-1665-6683
Kyung You	https://orcid.org/0000-0001-7583-5502

Publications in 2025 (1 January 2025 – 31 December 2025)

Journal Articles (RBWH staff or consumers in bold)

Bennett C, McLean LS, Lim, Bressel M, Guminski A, **Hughes BGM**, Bowyer SE, Stein B, Rischin D. Extended follow-up outcomes of Australian patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab on EMPOWER-CSCC-1. Journal of the American Academy of Dermatology 2025. doi.org/10.1016/j.jaad.2025.11.080. 2025 Nov 29

Brown T, Cooney L, Smith D, Elvin-Walsh L, Kern E, Ahern S, Porceddu S, Kenny L, **Hughes BGM**, Cartmill B, Hickman I. Comparison of prophylactic versus reactive tube feeding approaches on weight loss and unplanned hospital admissions in patients with head and neck cancer receiving chemoradiotherapy. Current Oncology 2025; 33(1): 5. doi.org/10.3390/curroncol33010005. 2025 Dec 21

Journal Articles (RBWH staff or consumers in bold)

Chiu V, Boytar A, Cunningham B, Skinner T, Turner J, Anderson D, Khan A, Bailey T, Porter-Steele J, Young L, Tuffaha H, Perrin L, Garrett A, **Goh J**, Rose G, Clifford B, Gomersall S, Korbie D, Constantin N, Li J, McCarthy AL. Enhancing treatment outcomes after gynaecological cancer (ACUMEN): a randomised controlled exercise trial protocol. *BMC Cancer*. 2025 Jul;25(1):1195. doi:10.1186/s12885-025-14298-3. Epub 2025 Jul 21

Courneya KS, Vardy JL, O'Callaghan CJ, Gill S, Friedenreich CM, Wong RKS, Dhillon HM, Coyle V, Chua NS, Jonker DJ, Beale PJ, Haider K, Tang PA, Bonaventura T, Wong R, Lim HJ, **Burge ME**, Hubay S, Sanatani M, Campbell KL, Arthuso FZ, Turner J, Meyer RM, Brundage M, O'Brien P, Tu D, Booth CM. Structured Exercise after Adjuvant Chemotherapy for Colon Cancer New England Journal of Medicine. 2025 June. doi:10.1056/NEJMoa2502760. Epub 2025 Jun 1

Damodaran S, Weeramange CE, Kenny L, Vasani S, **Hughes BGM**, Breik O, Punyadeera C. CTCs and ctDNA in Head and Neck Cancer: From Molecular Insights to Clinical Impact. *Cancer and Metastasis Reviews* 2025; 44(4): 88. doi.org/10.1007/s10555-025-10305-y. 2025 Dec 4

Dingemans AMC, Syrigos K, Livi L, Paulus A, Kim SW, Chen Y, Filip E, Griesinger F, Ohashi K, Zalzman G, **Hughes BGM**, Sørensen JB, Blais N, Ferreira CG, Lindsay CR, Dzadziuszko R, Ward PJ, Obiozor CC, Wang Y, Peters S. Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trial. *Lung Cancer*. 2025 Sep; 207:108683. doi:10.1016/j.lungcan.2025.108683. Epub 2025 Jul 29

Emmett L, Papa N, Subramaniam S, Crumbaker M, Nguyen A, Joshua AM, Sandhu S, Weickhardt A, Lee ST, Ng S, Francis RJ, **Goh JC**, Pattison DA, Tan T, Kirkwood ID, Ayati N, Niu C, Hofman MS, Martin AJ, Thomas H, Davis ID, Stockler MR. Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial. *Lancet Oncology*. 2025 Jul. doi:10.1016/S1470-2045(25)00339-0. Epub 2025 Jul 30

Emmett L, Subramaniam S, Crumbaker M, Joshua AM, Sandhu S, Nguyen A, Weickhardt A, Lee ST, Ng S, Francis RJ, **Goh JC**, Pattison DA, Tan TH, Kirkwood ID, Gedye C, Rutherford NK, Kumar AS, Pook D, Ramdave S, Nadebaum DP, Voskoboinik M, Redfern AD, Macdonald W, Krieger L, Schembri G, Chua W, Lin P, Horvath L, Bastick P, Butler P, Zhang AY, McJannett M, Thomas H, Langford A, Hofman M, Martin AJ, Davis AD, Stockler MR. Overall survival and quality of life with [¹⁷⁷Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from an open-label, multicentre, randomised, phase 2 trial. *The Lancet Oncology*. 2025 Feb. doi:10.1016/S1470-2045(25)00009-9. Epub 2025 Feb 13

Farley MJ, Scanlon B, Crichton M, Bigaran A, Barnes A, Hart NH, Yates PM, **Eastgate M**, Alexander K. Non-pharmacological Supportive Care Interventions during Immunotherapy for People with Cancer: A Systematic Scoping Review and Future Directions. *Curr Oncol Rep*. 2025 Dec;27(12):1507-1523. doi: 10.1007/s11912-025-01714-x. Epub 2025 Dec 6. PMID: 41350482; PMCID: PMC12743693

Hapgood G, Hill K, Okano S, Abro E, Looke D, Kennedy G, Pavilion G, Van Kuilenburg R, Geary A, Joubert W, **Eastgate M**, Jones M, Mollee P. Catheter-related thrombosis in adults with cancer: a secondary analysis of a prospective randomized controlled trial. *J Thromb Haemost*. 2025 Feb;23(2):627-634. doi: 10.1016/j.jtha.2024.11.002. Epub 2024 Nov 15. PMID: 39549836

Huang X, Leo P, Clout M, Fink L, Ellis J, **Hughes BGM**, **Kenny L**, Vasani S, Punyadeera C. Tumour informed workflow to use ctDNA as a biomarker for risk of recurrence in head and neck cancer patients post-treatment. *View* 2025. doi.org/10.1002/VIW.20250112. 2025 Sep 25

Huang X, Zhang X, Weeramange CE, Leo P, **Hughes BGM**, Dolcetti R, Zeng B, Hartel G, Ladwa R, Taheri T, Breik O, **Kenny L**, Vasani S, Punyadeera C. Development of a Circulating Tumour Cell Culture Model from Head and Neck Squamous Cell Carcinoma. *View* 2025; 6(6): 20250085. doi.org/10.1002/VIW.20250085. 2025 Oct 31

Hughes BGM, Guminski A, Bowyer S, Migden MR, Schmults CD, Khushalani NI, Chang ALS, Grob JJ, Lewis KD, Ansstas G, Day F, Ladwa R, Stein BN, Muñoz Couselo E, Meier F, Hauschild A, Schadendorf D, Basset-Seguin N, Modi B, Dalac-Rat S, Dunn LA, Flatz L, Mortier L, García-Castaño A, José Juan Fita M, Guégan S, Heinzerling LM, Mehnert JM, Trabelsi-Messai S, Soria-Rivas A, Stratigos AJ, Ulrich C, Wong DJ, Beylot-Barry M, Bossi P, Bugés Sánchez C, Chandra S, Robert C, Russell JS, Booth J, Yoo SY, Seeb. A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long term analysis of weight-based dose (Groups 1, 2, and 3), and primary analysis of fixed dose (Group 6). *Journal of American Academic Dermatology*. 2025 Jan;92(1):68-77. doi:10.1016/j.jaad.2024.06.108.

Ladwa R, Lee JH, McGrath M, Cooper C, Liu H, Bowman J, Gupta R, Cuscaden C, **Nottage M**, Clark JR, Le D, **Pauley M**, Kulasinghe A, Gonzalez-Cruz J, Porceddu S, **Hughes BGM**, Panizza B. Response-Adapted Surgical and Radiotherapy De-Escalation in Resectable Cutaneous Squamous Cell Cancer Using Pembrolizumab: The De-Squamate Study. *Journal of Clinical Oncology*. 2025 Sep;43(26):2888-96. doi:10.1200/JCO-25-00387. Epub 2025 Sep 10

Ledermann JA, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, **Goh JC**, O'Malley DM, Armstrong DK, Banerjee S, Garcia-Donas J, Swisher EM, Coleman RL. Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: final results of the phase 3, randomized, placebo-controlled ARIEL3 trial. *European Journal of Cancer*. 2025 Jun. doi:10.1016/j.ejca.2025.115584. Epub 2025 Jun 17

Lee CK, Liao BC, Subramaniam S, Chiu CH, Mersiades A, Ho CC, Brown C, Lai CL, **Hughes BGM**, Yang TY, O'Byrne K, Luo YH, Yip S, Ho CL, Bray V, Su WC, Moore M, Feng WL, Bai YY, Ford K, Cummins M, Stockler M, Solomon B, John T, Yang JCH. Durvalumab, tremelimumab and platinum chemotherapy in EGFR mutation positive non-small cell lung cancer - an open label phase 2 trial (ILLUMINATE). *JTO Clinical and Research Reports*. 2025 Feb;6(2):100771. doi:10.1016/j.jtocrr.2024.100771.

Journal Articles (RBWH staff or consumers in bold)

Machiels JP, Tao Y, Licitra L, Burtneess B, Tahara M, Rischin D, Alves GV, Lima IPF, **Hughes BGM**, Pointreau Y, Aksoy S, Laban S, Greil R, Burian M, Hetnal M, Delord JP, Mesia R, Taberna M, Waldron J, Simon C, Gregoire V, Harrington K, Black CM, Norquist JM, Wang A, Gumuscu B, Bidadi B, Siu LL. Health-related quality of life outcomes from KEYNOTE-412: Chemoradiotherapy with or without pembrolizumab in participants with head and neck squamous cell carcinoma. *Frontiers in Oncology* 2025; 15: 1645509. doi: 10.3389/fonc.2025.1645509. 6 Oct 2025

Melino M, Tu WJ, Bielefeldt-Ohmann H, Proctor M, Ahuja T, Vandermeide J, Bain AL, Nallan G, Goh SL, Prasanna T, Dahlstrom JE, Miranda M, Chaudhary RK, Anadam A, Chaudhary S, Seal JT, Sinha D, Zhang S, Nguyen TH, Sirhari S, Hartel G, **Ives A**, Malik L, Yip D, **Nottage M**, **Eastgate M**, Rao S. Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer *Molecular Cancer Therapeutics* 2025 Jun 17. doi.org/10.1158/1535-7163.MCT-24-0693

Murray-Douglass A, Crawford L, Hunt J, Dunn D, **Hughes BGM**, Lin C, Fox C. Survival following orbital exenteration for primary cutaneous squamous cell carcinoma, a retrospective cohort study. *Annal of Surgical Oncology* 2025. doi.org/10.1245/s10434-024-16854-w. 2025 Jan 13

Naei VY, Tubelleza R, Monkman J, Sadeghirad H, Donovan M, Blick T, Wicher A, Bodbin S, Stad R, Basu S, Barnett C, O'Byrne K, Ladwa R, Warkiani ME, **Hughes BGM**, Kulasinghe A. Spatial interaction mapping of PD-1/PD-L1 in Head and Neck Cancer reveals the role of Macrophage-Tumour Barriers associated with immunotherapy response. *Journal of Translational Medicine* 2025. doi:10.1186/s12967-025-06186-y. 2025 Feb 12

Oaknin A, Monk B, de Melo A, Kim H, Kin Y, Lisyanskaya A, Samouelian V, Lorusso D, Damian F, Chang C, Gotovkin E, Takahashi S, Ramone D, Mackowiak-Matejczyk B, Polastro L, Guerra Alia E, Colombo N, Makarova Y, **Goh J**, Hasegawa K, Mora P, Pikiel J, Srivastav R, Rischin D, Rubio M, Perez J, Yoo S, Gao B, Jamil S, Seebach F, Lowy I, Mathias M, Fury M, Tewari K. Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial. *European Journal of Cancer*. 2025. doi:10.1016/j.ejca.2024.115146. Epub 2025 Jan 10

Obermair A, Gebiski V, **Goh J**, Kuchel A, Brand A, Mak B, McNally O, Baxter E, Jobling T, Mileshekin L. Phase 2b, open-label, single-arm, multicenter pilot study of the efficacy, safety, and tolerability of dostarlimab in women with early-stage mismatch repair-deficient endometrioid endometrial adenocarcinoma. *International Journal of Gynecological Cancer*. 2025 Jan():101644. doi:10.1016/j.ijgc.2025.101644. Epub 2025 Jan 16

Pattison DA, Kong G, Akhurst T, **Burge M**, Chiang C, Hofman MS, Hung TJ, Love A, Michael M, Okano S, Ravi Kumar AS, Sachithanandan N, **Wyld D**, Hicks RJ. Peptide receptor radionuclide therapy in malignant insulinoma. *Endocrine-Related Cancer*. 2025 May. doi:10.1530/ERC-25-0018. Epub 2025 May 1

Rha SY, Castanon E, Gill S, Senellart H, Lopez J, Márquez-Rodas I, Victoria I, Kim TM, **Lwin Z**, Burger MC, Simonelli M, Cassier PA, Hendifar AE, Ascierto PA, Dutcus C, Okpara CE, Ghorri R, Jin F, Groisberg R, Villanueva L. Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: Results from the phase 2 LEAP-005 study recurrent glioblastoma cohort. *Cancer*. 2025 Aug; 131(16):e70015. doi:10.1002/cncr.70015. Epub 2025 Aug 13

Roberts MJ, Roberts NA, Pelecanos A, Yaxley JW, Harley SJ, Siriwardana AR, Cullen K, Prior M, Lindsay K, Vela I, **Kuchel A**, Dhiantravan N, Thomas P, Pattison DA. A prospective, multi-centre trial of PSMA-PET compared to FDG-PET for staging of newly diagnosed high risk prostate cancer. *EJNMMI research*. 2025 Jul; 15(1):92. doi:10.1186/s13550-025-01265-z. Epub 2025 Jul 24

Roberts NA, Davis ID, **Wyld D**, **Goh J**, Thompson M, Gedye C, Dhillon HM. How to Support Participants in Urogenital and Prostate Clinical Trials: A Qualitative Perspective. *Psycho-Oncology*. 2025 Jul;34(7):e70214. doi:10.1002/pon.70214. Epub 2025 Jul 14

Scanlon B, Roberts N, **Wyld D**, Toloo GS, Durham J. Institutional Factors Associated with Equitable Cancer Care Provision for Culturally and Linguistically Diverse Populations in Queensland, Australia: A Critical Race Theory Analysis. *Journal of Racial and Ethnic Health Disparities*. 2025 May. doi:10.1007/s40615-025-02477-8. Epub 2025 May 16

Tahara M, Greil R, Rischin D, Harrington KJ, Burtneess B, de Castro G, Psyrris A, Braña I, Neupane P, Bratland Å, Fuereder T, **Hughes BGM**, Mesia R, Ngamphaiboon N, Rordorf T, Ishak WZW, Lin J, Gumuscu B, Lerman N, Soulières D. Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study. *European Journal of Cancer*. 2025 May;221:115395. doi.org/10.1016/j.ejca.2025.115395. Epub 2025 May 15

Tan CW, Berrell N, Donovan ML, Monkman J, Sadeghirad H, Naei VY, Chen J, Rossenbloom A, Barnett C, Ladwa R, **Hughes BGM**, Kulasinghe A. The development of a high-plex spatial proteomic methodology for the characterisation of the head and neck tumour microenvironment. *npj Precision Oncology* 2025; 9: 191. https://doi.org/10.1038/s41698-025-00963-0. 2025 Jun 18

Tie J, Wang Y, Lo SN, Lahouel K, Cohen JD, Wong R, Shapiro JD, Harris SJ, Khattak A, **Burge ME**, Lee M. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial. *Nature Medicine*. 2025 Mar;1-10. doi:10.1038/s41591-025-03579-w. Epub 2025 Mar 7

Uppaluri R, Haddad RI, Tao Y, Le Tourneau C, Lee NY, Westra W, Chernock R, Tahara M, Harrington K, Klochikhin AL, Braña I, Alves GV, **Hughes BGM**, Oliva M, Lima IPF, Ueda T, Rutkowski T, Schroeder U, Mauz PS, Fuereder T, Laban S, Oridate N, Popovtzer A, Mach N, Korobko Y, Costa DA, Hooda-Nehra A, Rodriguez CP, Bell RB, Manschot C, Benjamin K, Gumuscu B, Adkins D. Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer. *New England Journal of Medicine*. 2025 Jun;393.37-50. doi:10.1056/NEJMoa2415434. Epub 2025 Jun 18

Xia Q, Senanayake SJ, Kularatna S, Brain D, McPhail SM, Parsonage W, **Eastgate M**, Barnes A, Brown N, Carter HE. Cost-effectiveness analysis of microwave ablation versus robot-assisted partial nephrectomy for patients with small renal masses in Australia. *Urol Oncol*. 2025 Jan;43(1):62.e15-62.e26. doi: 10.1016/j.urolonc.2024.09.016. Epub 2024 Oct 4. PMID: 39366793.

Journal Articles (RBWH staff or consumers in bold)

You KH, **Lwin Z**, Ahern E, **Wyld D**, Roberts N. Factors that Influence Clinical Trial Participation for Oncology Patients in Australia: A Scoping Review. *BMJ Open*. 2025 Jun 12;15(6):e095355. doi:10.1136/bmjopen-2024-095355.

Conference Presentations – Invited Speaker, Oral and Poster 2025

Invited Speaker (RBWH staff in bold) 2025

Brady J. From Radionuclides to Results: Bringing Nuclear Medicine to the Table. Australian and New Zealand Urogenital and Prostate Cancer Trials Group Annual Scientific Meeting. 2025 Jul 21.

Brady J. Half-Life, Full Team: Energising Multi Departmental Trials in Theranostics. Australian and New Zealand Urogenital and Prostate Cancer Trials Group Annual Scientific Meeting. 2025 Jul 21.

Goh JC: Incorporation of ADCs into the treatment paradigm for muscle invasive & metastatic bladder cancer. Brisbane Cancer Conference. 2025 Nov 27.

Nowak AK, Forde P, Brown C, **Hughes BGM**, Sun Z, Chin WL, John T, Glass Zauderer M, Ludlow A, O'Byrne KJ, Kindler HL, Kok PS, Ford K, Ramalingam SS, Yip S, Cook A, Anagnostou V, Pavlakakis N, Brahmer J, Stockler MR. Primary results of DREAM3R: DuRvalumab (MEDI4736) with chemotherapy as first line treatment in advanced pleural Mesothelioma - A phase 3 Randomised trial. *ESMO* 2025. Oct 19

Oral Presentations (RBWH staff in bold) 2025

Adkins D, Haddad RI, Tao Y, Tourneau CL, Lee NY, Westra W, Chernock R, Tahara M, Harrington K, Klochikhin AL, Braña I, Alves GV, **Hughes BGM**, Oliva M, Lima IPF, Ueda T, Manschot C, Benjamin K, Bidadi B, Uppaluri R. Neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC): Exploratory efficacy analyses of the phase 3 KEYNOTE-689 study. *American Society of Clinical Oncology Annual Meeting (ASCO)*. 2025 Jun 1.

Albiges L, Suarez C, Powles T, Motzer RJ, Stadler WM, Miller WH, Rojas C, Peer A, **Goh JC**, Park SH, Waddell T, Barthelemy P, Borau PG, Weickhardt A, Faoust G, Perini RF, Bousserouel L, Wang D, Hammers H, Beckermann KE. KEYMAKER-U03 Substudy 03B: Pembrolizumab and Targeted Therapy Combinations for Advanced Clear Cell Renal Cell Carcinoma. *American Society of Clinical Oncology Genitourinary Cancers Symposium*

Booth CM, Vardy JL, O'Callaghan CJ, Gill S, Friedenreich C, Wong RK, Dhillon HM, Coyle V, Chua NS, Jonker DJ, Beale PJ, Haider K, Tang PA, Bonaventura T, Wong R, Lim HJ, **Burge ME**, O'Brien P, Tu D, Courneya KS. A randomized phase III trial of the impact of a structured exercise program on disease-free survival (DFS) in stage 3 or high-risk stage 2 colon cancer: Canadian Cancer Trials Group (CCTG) CO.21 (CHALLENGE). *American Society of Clinical Oncology Annual Meeting (ASCO)* 2025 Jun 1.

Donovan ML, Sadeghirad H, Berrell N, Monkman J, Naei VY, Tan CW, Yunis J, West Z, Warkiani ME, Ladwa R, **Hughes BGM**, Da Gama Duarte J, Kulasinghe A. 2D and 3D spatial characterisation of tertiary lymphoid structures in head and neck cancer patients receiving immune checkpoint blockade therapy. *American Association for Cancer Research (AACR) Annual Meeting*. 2025 Apr 21.

Emmett L, Papa N, Subramaniam S, Crumbaker M, Nguyen A, Joshua AM, Sandhu S, Weickhardt A, Lee S, Ng S, Francis RJ, **Goh JC**, Pattison DA, Tan TH, Kirkwood ID, Ayati N, Niu C, Hofman MS, Martin AJ, Thomas H, Davis ID, Stockler MR. Predictive and prognostic value of baseline PSMA-PET total tumor volume and SUV mean within ENZA-p, a randomized phase II trial of enzalutamide versus enzalutamide plus [177Lu] Lu-PSMA-617 (ANZUP1901). *American Society of Clinical Oncology Annual Meeting (ASCO)*. 2025 Jun 2.

Emmett L, Subramaniam S, Crumbaker M, Nguyen A, Joshua AM, Weickhardt A, Lee ST, Ng S, Francis RJ, **Goh JC**, Pattison DA, Tan TH, Kirkwood ID, Sandhu S, Zhang AY, Hofman M, Thomas H, Martin AJ, Davis ID, Stockler MR. Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from an open-label, multicentre, randomised, phase 2 trial. *American Society of Clinical Oncology Genitourinary Cancers Symposium*

Kheam B, Michel L, Machiels JP, Oosting S, **Hughes BGM**, Park JC, Forgie AJ, Brickman D, Tsiatis AC, Sandler A, Harrington K. ASPEN-03: A randomized phase 2 study of Evorpaccept (Evo) in combination with Pembrolizumab (P) in patients with recurrent, unresectable or metastatic (R/M) PD-L1 positive head and neck squamous cell carcinoma (HNSCC). *ESMO* 2025 Oct 19

Lee CK, Zhou D, Brown C, Bray V, Ding P, Itchins M, **Hughes BGM**, Houghton B, Chan B, Black A, Solomon B, Roberts-Thomson R, Mersiades A, Parakh S, Bain N, Yip S, Barton K, Cummins M, Wall M, Goodwin A, Pavlakakis N, John T, Mitchell P, Arulananda S. Primary Endpoint Results from SHERLOCK: Phase II Study of Sotorasib, Bevacizumab and Chemotherapy in Advanced KRAS G12C NSCLC. *World Conference on Lung Cancer*. 2025 Jul 20.

Lee NY, Adkins D, Haddad RI, Tao Y, Le Tourneau C, Westra W, Chernock R, Tahara M, Harrington K, Klochikhin AL, Carrasco RG, Alves GV, **Hughes BGM**, Oliva M, Lima IPF, Ueda T, Manschot C, Benjamin K, Gumuscu B, Uppaluri R. Neoadjuvant and Adjuvant Pembrolizumab (Pembro) Plus Standard of Care (SOC) in Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC): Postoperative Risk Subgroup Analysis of KEYNOTE-689. *ASTRO* 2025 Sep 30

Oral Presentations (RBWH staff in bold) 2025

Nowak AK, Forde P, Brown C, **Hughes BGM**, Sun Z, Chin WL, John T, Glass Zauderer M, Ludlow A, O'Byrne KJ, Kindler HL, Kok PS, Ford K, Ramalingam SS, Yip S, Cook A, Anagnostou V, Pavlakis N, Brahmer J, Stockler MR. Impact of changing clinical practice on DREAM3R: DuRvalumab (MEDI4736) with chemotherapy as first line treatment in advanced pleural Mesothelioma - A phase 3 Randomised trial. iMig 2025 Oct 28

Sandhu S, Subramaniam S, Thomas H, Tan TH, **Goh JC**, Dhiantravan N, Weickhardt AJ, Joshua AM, Kirkwood ID, Lee ST, Gedye C, Nguyen A, Pattison DA, Alipour R, Francis RJ, Hofman MS, Martin AJ, Stockler MR, Davis ID, Emmett L. 177 Lu -PSMA -617 with ipilimumab and nivolumab in metastatic castration-resistant prostate cancer (mCRPC): an investigator-initiated phase 2 trial (EVOLUTION; ANZUP2001). American Society of Clinical Oncology Annual Meeting. 2025 Jun 1.

Tao Y, Adkins D, Haddad RI, Tourneau CL, Lee NY, Westra W, Chernock R, Tahara M, Harrington K, Klochikhin AL, Braña I, Alves GV, **Hughes BGM**, Oliva M, Lima IPF, Ueda T, McQuarrie K, Manschot C, Benjamin K, Uppaluri R. Neoadjuvant-adjuvant (neoadj-adj) pembrolizumab (pembro) plus standard of care (SOC) in Resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC): Participant-reported outcomes (PRO) in KEYNOTE-689. ESMO 2025 Oct 19

Tao Y, Siu L, Licitra L, Burtneess B, Tahara M, Rischin D, Alves GV, Lima IPF, **Hughes BGM**, Pointreau Y, Aksoy S, Laban S, Greil R, Burian M, Hetnal M, Delord JP, Kassalow L, Bidadi B, Gumuscu B, Machiels JP. Long-term results of the randomized, phase 3 KEYNOTE-412 trial of pembrolizumab (pembro) or placebo (pbo) plus concurrent chemoradiotherapy (CRT) for unresected, locally advanced head and neck squamous cell carcinoma (LA HNSCC). American Society of Clinical Oncology Annual Meeting (ASCO). 2025 Jun 1.

Tie J, Wang Y, Loree JM, Cohen JD, Espinosa D, Wong R, Price TJ, Tebbutt NC, Lee M, **Burge ME**, Harris SJ, Lee B, Lynam JF, O'Callaghan CJ, Breadner DA, Bettgeowda C, Papadopoulos N, Kinzler KW, Vogelstein B, Gibbs P. ctDNA-guided adjuvant chemotherapy escalation in stage III colon cancer: Primary analysis of the ctDNA-positive cohort from the randomized AGITG Dynamic-III trial (intergroup study of AGITG and CCTG). American Society of Clinical Oncology Annual Meeting (ASCO). 2025 May 30.

Uppaluri R, Tao Y, Haddad RI, Lee NY, García IB, Ueda T, Klochikhin A, **Hughes BGM**, Lima IPF, Alves GV, Mauz PS, Bernal MO, Füreder T, Mach N, Oridate N, Laban S, Manschot C, Benjamin K, Gumuscu B, Adkins D. Perioperative pembrolizumab in patients with resectable locally advanced head and neck squamous-cell carcinoma (LA HNSCC): Results from KEYNOTE-689. American Association for Cancer Research (AACR) Annual Meeting. 2025 Apr 21.

Poster Presentations (RBWH staff in bold) 2025

Ahmed S, Yang J, Kobayashi K, Valdiviezo N, Yu Y, Fan Y, Yan TY, Kim TM, **Hughes BGM**, Andrasina I, Koubkova L, Geater SL, Maurel JM, Rojas C, Pham XD, Bing JTC, Bhise R, Cundom J, Shepherd F, Barrett K, Cheng Y. First-Line Osimertinib ± Platinum-Pemetrexed In EGFR-Mutated Advanced NSCLC: FLAURA2 Clinical Outcomes by EGFRm Subtype. World Conference on Lung Cancer. 2025 Sep 6.

Ahmed S, Yang J, Kobayashi K, Valdiviezo N, Yu Y, Fan Y, Yan TY, Kim TM, **Hughes BGM**, Andrasina I, Koubkova L, Geater SL, Maurel JM, Rojas C, Pham XD, Bing JTC, Bhise R, Cundom J, Shepherd F, Barrett K, Cheng Y. First-Line Osimertinib ± Platinum-Pemetrexed In EGFR-Mutated Advanced NSCLC: FLAURA2 Clinical Outcomes by EGFRm Subtype. WCLC 2025 Sep 9

Alexander M, Itchins M, Kao S, Nagril A, Brown LJ, Bowyer S, Parakh S, Moore M, Kong B, Yeo N, **Hughes B**, Arulananda S, Chin V, Warburton L, Khoo T, Mersiaes AJ, Leigh L, Rogers J, Spelman T, Pavlakis N, Solomon B. Real-World Insights on Treatment Patterns and Outcomes in ROS1+ NSCLC: An Australian Multicenter Study (AURORA). WCLC 2025 Sep 7

Burge M, Wyld D, Pattison D, Loree J, Goodwin R, Chantrill L, Karapetis C, Barker D, Bahamad S, Hayes SA, Kuszewski J, Mak WJ. AGITG STOPNET: A randomized study of cessation of somatostatin analogues after peptide receptor radionuclide therapy in mid, hind-gut and pancreatic neuroendocrine tumours. European Neuroendocrine Tumor Society Annual Congress

Burge ME, Wyld DK, Pattison D, Bahamad S, Hayes S, Kuszewski J, Chantrill L, Price T, Wong H, Chad D, Grover P, Michael M, Sie D, Bishop C, Barker D, Goodwin R, O'Callaghan C, Loree J, Mak WJ. Australasian Gastro-Intestinal Trials Group (AGITG) STOPNET: A randomized study of cessation of somatostatin analogues (SSA) after peptide receptor radionuclide therapy (PRRT) in mid, hind-gut, and pancreatic neuroendocrine tumours. American Society of Clinical Oncology Annual Meeting (ASCO). 2025 May 31.

Dowlati A, Ahn MJ, Azambuja AA, Byers L, Califano R, Cappuzzo F, Cheng Y, Girard N, Hendriks L, **Hughes B**, Kutiel TS, Mountzios G, Takahama T, Thomas M, Yang CH, Patel J, Park J, Wu T, Paz-Ares L. A Phase 3 Study of Sacituzumab Govitecan in Patients With Previously Treated Extensive Stage Small Cell Lung Cancer. World Conference on Lung Cancer. 2025 Sep 6.

Goh J, Brady J, Pattison DA, Ngai S, Katchel L, Holmes I, Baker S, Biggs H, Cuscaden C, Campbell L, Lindsay K, Latter M, Griffiths M, O'Mahoney E, Dhiantravan N, Francis R, Rose S, Soderholm A, Baronet M, Crumbaker M, Kryza T, Shakti S, Naidoo S, Puttick S, Horsfall A, Barkhausen C, Kuan K, Santoro P, Skingley L, Tieu W, **Kuchel A, Gan CL, Wyld DK**, Hansen A. Phase Ib/IIa dose escalation and expansion study of [212Pb]Pb-ADVC001 in metastatic castration-resistant prostate cancer: TheraPb-phase I/II study. Australian and New Zealand Urogenital and Prostate Cancer Trials Group Annual Scientific Meeting. 2025 Jul 21.

Hansen A, Pattison D, Ngai S, Karmann A, Walker A, Campbell L, **Brady J**, Katchel L, Holmes I, Rose S, Baronet M, Kryza T, Vito A, Tieu W, Kuan K, Griffiths M, O'Mahoney E, Latter M, **Gan CL, Wyld D**. Phase Ib/IIa dose escalation and expansion study of [212Pb]Pb-ADVC001 in metastatic castration-resistant prostate cancer: TheraPb-phase I/II study. American Society of Clinical Oncology Genitourinary Cancers Symposium

Poster Presentations (RBWH staff in bold) 2025

McLachlan SA, Mostafa R, Sharpe L, **Burge ME**, Day F, Blum RH, Campbell R, Lynam JF, Lee B, Singh MS, Lee M. Circulating tumor DNA (ctDNA) analysis guiding adjuvant therapy in patients (pts) with colorectal cancer (CRC): Impact on fear of cancer recurrence (FCR). American Society of Clinical Oncology Annual Meeting (ASCO). 2025 Jun 1.

Norman C, Sachdeva K, Ji1 P, Grantham S, Leigh N, Tsao MS, Goss G, Laurie S, Vera-Badillo F, Bradbury PA, **Hughes B**, Stockler M, Uriarte A, Olanrewaju M, Fotheringham M, Othman A, Radwan E, Dancey J, Ding K, Cottrell T. Investigating tumor associated neutrophils as predictors of therapeutic response in advanced non-small cell lung cancer. WCLC 2025 Sep 8

Suarez C, Albiges L, Beckermann KE, Hammers H, Stadler WM, Miller WH, Rojas C, Peer A, **Goh JC**, Park SH, Waddell T, Barthelemy P, Borau P, Weickhardt A, Faust G, Perini RF, Bousserouel L, Wang D, Motzer RJ, Powles T. KEYMAKER-U03 Substudy 03B: Pembrolizumab and Novel Immunotherapy Agents for Advanced Clear Cell Renal Cell Carcinoma. American Society of Clinical Oncology Genitourinary Cancers Symposium

Cancer Care Nursing Research

Research highlights



Mr Michael Smith

Director Cancer Nursing, RBWH

2025 was an exciting and productive year for the Cancer Care Nursing Research Department. Led by Professor Kim Alexander and Dr Brigid Scanlon, the team made excellent progress on the priorities set out in the Nursing Research Action Plan (2024–2027). The team was also pleased to welcome Emma Munro to the Nurse Researcher team. Emma is a respected nursing leader in haematology and bone marrow transplant and brings a wealth of clinical expertise and research knowledge to the team.

A key achievement for the year was securing a highly competitive Medical Research Futures Fund grant, led by Professor Alexander and valued at \$984,737. This important project will focus on improving the uptake of clinical genomics across Cancer Services in Queensland. Chief Investigators from Cancer Care Services include Nurse Researcher Dr Brigid Scanlon, Nursing Director Michael Smith, Associate Professor David Wyld and Associate Professor Glen Kennedy. In addition, Professor Alexander and Dr Scanlon secured \$65,000 in Royal Brisbane and Women's Hospital Project Grant funding across two projects. Dr Scanlon was also awarded the Carla Patterson Memorial Grant Award from QUT Health, valued at \$15,000. The team also successfully secured two Royal Brisbane and Women's Hospital Fellowship Grants, with Dr Scanlon receiving an Early Career Research Fellowship and Emma Munro being awarded a Higher Degree Research Scholarship, each valued at approximately \$78,000.

2025 was also an exciting year for our Higher Degree Research students. Hannah Warriner successfully completed her PhD articulation seminar, and Courtney Black officially completed her Master of Philosophy. We congratulate both Hannah and Courtney on these significant achievements.

Throughout 2025, the Nursing Research team was well represented at both local and national conferences. Professor Alexander presented at the Queensland Health Office of Research and Innovation Inspired Showcase, the Cancer Nursing Society of Australia Conference, the Brisbane Cancer Conference, and took part in a live recording of the *Five Things Podcast*, speaking on Innovation and Adaptation. Dr Scanlon presented at the Clinical Oncology Society of Australia, the Cancer Care Research Forum and was awarded Best Oral Presentation (Research) at the Metro North Research Showcase. The Metro North Showcase also saw oral presentations from Courtney Black and Michael Smith, with Courtney winning the Best Higher Degree Research Award and Michael being placed in top 5 presentations for innovation. Emma Munro presented at the Cancer Nursing Society of Australia Conference and both Emma and Hannah Warriner presented at the Nursing and Midwifery Research Centre Grand Rounds.

During 2025 the Nursing Research team have continued supporting the clinical environments to engage with research projects and participate in our Evidence Based Practice Program and Research Internships. We congratulate the entire team on a fantastic year and look forward to an exciting 2026.

Successful Research Higher Degree (e.g. MPhil or PhD) candidates in 2025

Name	Degree (e.g. MPhil or PhD)	Title	Month Completed	Affiliated University	Summary
Courtney Black	Master of Philosophy	Preventing Iatrogenic Anaemia in Malignant Haematology Inpatients: a cross-sectional survey and randomised controlled trial.	December, 2025	Queensland University of Technology	Patients receiving treatment for haematological malignancies are highly susceptible to anaemia due to disease processes, intensive therapies, and frequent laboratory monitoring. Reducing iatrogenic blood loss is therefore a critical component of patient blood management (PBM) and an important target for quality improvement in cancer care. This MPhil program aimed to (1) identify barriers and enablers to implementing evidence-based blood conservation practices in inpatient haematology units, and (2) pilot a co-designed, multicomponent intervention to support low-volume blood sampling and improved phlebotomy practices.



Research Awards and Achievements

Recipient (RBWH staff in bold)	Award	Event
Hannah Warriner	QUT MPhil Stipend	\$30,000 per annum (2024-2027)
Emma Munro	Metro North Health Pre-Research Higher Degree Scholarship	\$15,000 (2025-2026)
Brigid Scanlon	Carla Patterson Memorial Grant Award	\$15,000 (2025)
Emma Munro	RBWH Research Higher Degree Scholarship	\$76,395 (2026-2027)
Brigid Scanlon	RBWH Early Career Researcher Fellowship Grant	\$78,935 (2026-2027)
Brigid Scanlon	Best Oral Presentation (Research Award)	\$1000 Metro North Research Showcase
Courtney Black	Best Oral Presentation (Higher Degree Research)	\$1000 Metro North Research Showcase

Research Grants

Investigator Names (RBWH staff in bold)	RBWH Departments / Research Groups	Research Project Title	Granting Body	Total Awarded (whole all years)	Length of Awards in years and years active
Kim Alexander, Morgan Farley, Melissa Eastgate, Michael Smith, Claire Blake, Janine Deevy, Brigid Scanlon	Cancer Care Services	Co-design of a multidisciplinary wellness model of care to improve treatment outcomes for people receiving immunotherapy	RBWH Research Project Grant	\$15,000	2
Brigid Scanlon, David Wyld, Natasha Roberts, Michael Smith, Jo Durham, Alison Alexander, Morgan Farley, Kim Alexander	Cancer Care Services	Utilising the Equity Process Framework to promote equity in cancer through service improvements: A pilot study to reduce failure to attend appointments	RBWH Research Project Grant	\$49,907	2

Investigator Names (RBWH staff in bold)	RBWH Departments / Research Groups	Research Project Title	Granting Body	Total Awarded (whole all years)	Length of Awards in years and years active
Kim Alexander, Brigid Scanlon, Morgan Farley, Michael Smith, David Wyld, Glen Kennedy, Jacinta Smith	Cancer Care Services	The Nursing Compendium for Genomic-Informed Care (NGenCare)	Medical Research Futures Fund	\$984,737	2
Brigid Scanlon, David Wyld, Natasha Roberts, Kim Alexander	Cancer Care Services	From Indicators to Impact: Co-designing a Standardised Set of Essential Cancer Equity Indicators to Guide Universal Health Coverage Systems	Carla Patterson Memorial Grant Award (QUT Health)	\$15,000	1

RBWH Department / Research Group Lead Research Activity

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
Mary-Ellen Yarker	Carol Windsor (QUT) Jennifer Fox (QUT) Pauline Gillan (QUT)	The role of oncology nurse in shared decision making for patients undergoing radiation and/or chemotherapy treatment		Ongoing
Judy Avery	Sonya Osborne (USQ), Aletha Ward (USQ), Catriona Brooker (USQ)	Nurse-led debriefing with hospital nurses in the workplace		Ongoing
Hannah Warriner, Kim Alexander, Nicole Gavin		The psychological experience of oncology patients secondary to a hypersensitivity reaction		Ongoing
Emma Munro, Brigid Scanlon, Nicole Gavin, Michaela Teevan, Eleanor Green, Cameron Curley, Michael Smith		Development of a clinical pathway for mucositis assessment and management in haematopoietic stem cell transplantation: Improving practice and standardising nursing care		Ongoing
Yu-Meng Shu, Brigid Scanlon, Ilona Lillington, Nicole Gavin, Phillip Chan, Robyn Cheuk, Joyce Souza, Allison Dry, Jemma Blyth, Michael Smith		Developing a standardised clinical pathway for the management of Gynaecological and Prostate Brachytherapy		Ongoing
Emma Munro, Brigid Scanlon, Kim Alexander	Patsy Yates (QUT)	The hidden burden and impact of emerging cellular therapies on supportive care needs in the acute haematology and bone marrow transplant setting		Ongoing
Kim Alexander, Brigid Scanlon	Morgan Farley	Genomics in Nursing and Midwifery: A workforce development project		0

Collaborative Research Activity Involving RBWH Department / Research Group

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
Emily N Larsen, Claire M Rickard, Nicole Marsh, Mary Fenn, Rebecca S Paterson, Amanda J Ullman, Raymond Chan, Vineet Chopra, Doreen Tapsall, Amanda Corley, Nicole Gavin, Brighid Scanlon, Joshua Byrnes		Patient reported outcome and experience measures among patients with Central Venous Access Devices		Ongoing
Natasha Roberts, Michael Smith, David Wyld, Teresa Brown, Leonie Naumann, Erin Molloy, Suzette Fox, Greg Lewis, Mandy Fairclough, Maree Gier, Kieren Barker, Therese Hayes, Jenni Leutenegger, Nicole Gavin and Elise Button.	Gary Power (RBWH Consumer) and Helene Jacmon (Consumer representative)	A co-designed implementation science strategy with clinicians, consumers and researchers to structure improved nurse-led symptom management in medical oncology care		Ongoing

Research Publications

Authors

Investigator	ORCID ID
Brighid Scanlon	https://orcid.org/0000-0002-9190-8721
Kim Alexander	https://orcid.org/0000-0003-3906-2412
Nicole Gavin	https://orcid.org/0000-0002-0828-9852
Veronica Percival	https://orcid.org/0000-0001-7821-8710
Patsy Yates	https://orcid.org/0000-0001-8946-8504
Hannah Warriner	https://orcid.org/0009-0009-3931-3147
Emma Munro	https://orcid.org/0009-0005-3936-6637

Publications in 2025

Journal Articles (RBWH staff or consumers in bold)

Bradford, N., Cashion, C., Sharwood, E., Rumble, S., Condon, P., Cossio, D., Stratton, H., Ekberg, S., Semerci, R., Bowers, A., Pole, J., & **Alexander, K.** (2025). Co-Design and Evaluation Protocol for the RECOVER Model of Care After Childhood Cancer Treatment. *Healthcare*, 13(5), 454. <https://doi.org/10.3390/healthcare13050454>

Scanlon, B., Roberts, N., **Wyld, D.** *et al.* Institutional Factors Associated with Equitable Cancer Care Provision for Culturally and Linguistically Diverse Populations in Queensland, Australia: A Critical Race Theory Analysis. *J. Racial and Ethnic Health Disparities* (2025). <https://doi.org/10.1007/s40615-025-02477-8>

Morgan J. Farley, Brighid Scanlon, Megan Crichton, Ashley Bigaran, Amy Barnes, Nicolas H. Hart, Patsy M. Yates, **Melissa Eastgate, Kim Alexander**. Non-pharmacological supportive care interventions during immunotherapy for people with cancer: A systematic scoping review and future directions. *Current Oncology Reports* (2025).

Kim Alexander, Morgan J. Farley, Brighid Scanlon, Jed Duff. Role of nursing and midwifery in mainstreaming genomics in Australia: mixed-methods study exploring scope of practice and strategies for implementation. *Frontiers in Genetics* (2025).

Energy conservation education intervention for people with end-stage kidney disease receiving haemodialysis (EVEREST): A two-arm parallel group study, Sharma, Sita, **Alexander, Kim E.**, Green, Theresa L., Wu, Minlin, Bonner, Ann J. *International Journal of Nursing Studies* Open source preview, 2025, 166, 105032

Keynote or Plenary Lectures given in 2025

Date	Title
29.4.25	Kim Alexander: <i>Cancer Nursing Research Update</i> . Integrated Cancer Research (ICARE) Collaborative Research Retreat . April 2025.
29.5.25	Kim Alexander: Defining and enabling Nursing and Midwifery Genomics Practice. Queensland Health Office of Research and Innovation Inspired Showcase . May, 2025.
29.5.25	Kim Alexander: Genomic analysis for post-chemotherapy outcomes in cancer survivorship . Open Innovation Pitch. Queensland Health Office of Research and Innovation Inspired Showcase . May, 2025.
18.6.25	Michael Smith, Paul Moran, Annette Barnes, Ellen Kelly, Kieren Barker, Alison Alexander, Justine Leach, Kristen Lorrimer, Therese McCurry : Cancer Care Services Nursing Leadership Program. Cancer Nursing Society of Australia . June, 2025.
18.6.25	Emma Munro : Development of a clinical pathway for mucositis assessment and management in haematopoietic stem cell transplantation: Improving practice and standardising nursing care. Cancer Nursing Society of Australia . June, 2025.
23.6.25	Kim Alexander: Genomics 101 Webinar. Cancer Nursing Society of Australia . June, 2025.

03.7.25	Emma Munro: RBWH Cancer Care Services Research Internship Program Case Example- Development of a clinical pathway for mucositis assessment and management. <i>Nursing and Midwifery Research Centre Grand Rounds.</i> July 2025.
03.7.25	Hannah Warriner: RBWH Cancer Care Services Evidence-Based Practice Program Case Example- A review of the psychological experience of oncology patients following a hypersensitivity reaction. <i>Nursing and Midwifery Research Centre Grand Rounds.</i> July 2025.
16.09.25	Kim Alexander, Brighid Scanlon, Morgan Farley. Co-design in Cancer Research. Cancer Care Services Research Forum
7.11.25	Courtney Black. <i>Cross-sectional survey of the barriers and enablers to preventing iatrogenic anaemia in inpatients with haematological malignancies.</i> Metro North Research Showcase
7.11.25	Brighid Scanlon. <i>How equity in cancer services has been defined and measured, and why it matters: A systematic scoping review and future directions for clinical services.</i> Metro North Research Showcase
7.11.25	Michael Smith. <i>The Cancer Care Services Nursing Leadership Program.</i> Metro North Research Showcase
27.11.25	Kim Alexander. Bridge Building: Cancer Nurses at the intersection of clinical and genetic care. <i>Brisbane Cancer Conference.</i> November, 2025
7.11.25	Kim Alexander. Genomics in Australian nursing and midwifery practice: A mixed-method workforce development project. Live Podcast Recording. Metro North Research Showcase

QUT researchers secure million-dollar boost to create a more equitable cancer care system

[Home](#) > [Study](#) > [Health](#) > [News](#) > QUT researchers secure million-dollar boost to create a more equitable cancer care system



Professor Kim Alexander, Dr Brighid Scanlon and Dr Morgan Farley. Press Release for Medical Research Futures Fund Grant.

Allied Health Professions

Research highlights



Dr Clare Burns

**Advanced Speech Pathologist (Cancer Care)
Speech Pathology Department**

Across 2025, Allied Health Professions has continued to strengthen and expand its cancer care research program. Our research is embedded within the multidisciplinary teams of radiation oncology, medical oncology, haematology/BMT, and we highly value our ongoing collaboration with services such as QIMR Berghofer Medical Research Institute, Queensland PET Service, Gastroenterology, ENT, Maxillofacial surgery and others who form part of our cancer focused research teams. This year we have continued our research collaborations with major academic and clinical centres of excellence across Australia as well as the partnerships with teams in the USA.

Across 2025 Allied Health Professions has led a diverse range of studies engaging our consumers, clinicians, and other stakeholders to examine key aspects of cancer care delivery. These studies have incorporated exploring the application of new technologies to support diagnostics and management, the evaluation of emerging treatments to optimise support care needs and clinical outcomes and patient and caregiver consultation and co-design to enhance our education pathways and clinical service delivery.

Allied Health Professions' high quality and translational cancer care research has been recognised through several achievements. Key highlights include:

- Ms Sarah Wilson's (Speech Pathology) MPhil degree was conferred by The University of Queensland. Sarah's research program used international e-Delphi methodology facilitated by expert speech pathologists, to develop two draft evidence-based frameworks for the delivery of swallow assessment following laryngectomy. Together these frameworks will be used to inform clinical practice and guide future research in laryngectomy dysphagia assessment.
- Dr Sarah Anderson (Dietetics and Food Services) and research team has continued to extend their research program in haematology. They were awarded over \$250,000 in a series of grants exploring prebiotic fibre supplementation during allogeneic stem cell transplantation. Sarah is also a co-researcher on the NHMRC funded Centre of Research Excellence in Supportive Care for People with Blood Cancers.
- Dr Laura Moroney, Elise Treleavan and team were awarded the Allied Health and Nursing Grant Best Oral Presentation at the 2025 Australia and New Zealand Head and Neck Cancer Society Meeting for the study titled "Enhancing Swallowing and Nutrition Care: Practical Steps to Implement PROMS in Head and Neck Cancer". Dr Sarah Anderson, Francis Thomsen, Dr Clare Burns and teams also received awards for their research at national conferences.

Successful Research Higher Degree (e.g. MPhil or PhD) candidates in 2025

Name	Degree (e.g. MPhil or PhD)	Title	Month Completed	Affiliated University	Summary
Sarah Wilson 	MPhil	Clinical and radiological examination of swallowing following laryngectomy: International e-Delphi consensus processes.	June 2025	University of Queensland	Laryngectomy surgery causes permanent anatomical changes that significantly affect swallowing, yet core components of dysphagia assessment in this population remain undefined. This thesis aimed to establish consensus on essential tasks, observations, and measures for clinical swallow examinations (CSE) and video fluoroscopic swallowing studies (VFSS) following laryngectomy. Using international e-Delphi methodology, expert speech pathologists identified and refined assessment elements across two studies. Study 1 established 34 core CSE components, while Study 2 identified 28 key VFSS elements. Together, these findings provide a draft evidence-based framework that can be used to inform clinical practice and guide future research in laryngectomy dysphagia assessment.

Research Awards and Achievements

Recipient (RBWH staff in bold)	Award	Event
Laura Moroney, Elise Treleaven, Clare Burns, Teresa Brown	Allied Health and Nursing Grant - Best Oral Presentation	2025 Australia and New Zealand Head and Neck Cancer Society Meeting
Sarah Anderson	Best Abstract	2025 Australia and New Zealand Transplant and Cellular Therapies Conference
Francis Thomsen	Commendation - clinical paper	Australian Hand Therapy Association Conference, August 2025
Clare Burns , Trevor Russell, Joshua Simmich, Robert Cuthbert, Rebecca Cremer , Caitlin Fraser, Annie J Hill.	Best Scientific Poster Award	2025 Herston Health Symposium

Research Grants

Investigator Names (RBWH staff in bold)	RBWH Departments / Research Groups	Research Project Title	Granting Body	Total Awarded (whole all years)	Length of Awards in years and years active
Claire Blake, Elise Treleaven, Teresa Brown, Belinda Camilleri	Dietetics and Food Services	Implementation of Patient-led Nutrition Screening in Radiation Therapy	Metro North Health	\$ 9,177	2026

Investigator Names (RBWH staff in bold)	RBWH Departments / Research Groups	Research Project Title	Granting Body	Total Awarded (whole all years)	Length of Awards in years and years active
Laura Moroney , Laurelie Wishart, Clare Burns , Michelle Fenech, Penelope MacKenzie, Liz Ward, Kalnisha Appavoo-Juhasz, Roslyn Stray	RBWH (Speech Pathology, Radiation Oncology), Metro North (Office of Chief Allied Health Officer), Metro South Health, UQ, Griffith University, QUT	Feasibility of Ultrasound Imaging of Late Radiation Treatment Effects in Head and Neck Cancer Survivors (ULTRA Late-RAD).	Metro North Health	\$15,000	2025-2026
Rhiannon Young	Dietetics and Food Services	Person-centred nutrition care in palliative cancer care	Metro North Health	\$15,000	2024-2025
Sarah Andersen	Dietetics and Food Services	Using prebiotic fibre supplementation to improve patient outcomes during treatment for haematological malignancies	MNHHS Clinician Research Fellowship	\$240,531	2023-2027
Sarah Anderson	Dietetics and Food Services	Using prebiotic fibre supplementation to improve patient outcomes during treatment for haematological malignancies	Metro North Health	\$20,000	2025
Sarah Andersen , Heidi Staudacher (Deakin Uni), Nicole Gavin (Cancer Care, nursing), Andrea Henden (QIMR, UQ)	Dietetics and Food Services, Cancer Care Services	Prebiotic fibre supplementation during allogeneic stem cell transplantation, a pilot randomised control trial	ASPEN Rhoades Research Foundation	\$36,250	2026
Sarah Andersen , Heidi Staudacher (Deakin Uni), Nicole Gavin (Cancer Care, nursing), Andrea Henden (QIMR, UQ)	Dietetics and Food Services, Cancer Care Services	Prebiotic fibre supplementation during haematological cancer treatment	Gateway for Cancer Research	\$165,000	2024-2026
Sarah Andersen , Andrea Henden, Glen Kennedy, Midori Nakagaki, Nicole Gavin, Heidi Staudacher (Deakin Uni)	Nutrition Research Collaborative, Clinical Haematology	IMPACT BMT Trial	CCS trust fund	\$ 27,703	2025
Sarah Andersen , Rachel Willims	Nutrition Research Collaborative	Micronutrient requirements post stem cell transplantation and during graft versus host disease, implementation of evidence into practice	Office of Research and Innovation	\$ 4,963	2025

Investigator Names (RBWH staff in bold)	RBWH Departments / Research Groups	Research Project Title	Granting Body	Total Awarded (whole all years)	Length of Awards in years and years active
Sarah Wilson, Joanne Hiatt, Gemma Blyth, Joyce Souza, Clare Burns, Penny Mackenzie, Teresa Brown	Speech Pathology, Nutrition, Dietetics, Radiation Oncology, Cancer Care Nursing	Patient education pathway for patients with head and neck cancer (HNC) undergoing radiotherapy at RBWH.	RBWH Foundation	\$ 39,087	2025-2026
Teresa Brown	Nutrition and Dietetics	Optimising nutrition outcomes and care pathways for patients undergoing surgical resection for head and neck cancer	MNHHS Clinician Research Fellowship	\$175,000	2022-2025
Zoe McQuilton, Erica Wood, Claire Rickard, Meera Agar, Eliza Hawkes, Andrea Henden, Jason Roberts, Dennis Petrie, Claudia Rutherford, Thao Le, Aleece MacPhail, Sarah Andersen , Catriona Parker, Adam Irving, Allison Mo	Nutrition Research Collaborative and Monash University	A Centre of Research Excellence in Supportive Care for People with Blood Cancers	NHMRC	\$ 3,000,000	2026-2030

RBWH Department / Research Group Led Research Activity

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
Clare Burns	Atiyeh Vaezipour (UQ), Meghan Currant (Speech Pathology); Sarah Heaton (Speech Pathology); Caitlin Fraser (STARS); Annie Hill (UQ; STARS) Trevor Russell (UQ)	Telehealth delivery of an immersive virtual reality therapy tool for individuals with communication disorders: A feasibility study	Involvement	10
Clare Burns	Annie Hill (UQ), Liz Ward (CFAHR; UQ), Sanjeewa Kularatna (AusHSI QUT); Joshua Byrnes (Griffith University)	Evaluation of two speech pathology service models for swallowing rehabilitation post head and neck cancer treatment	Involvement	Not applicable
Lauren Rae	Emma Foley	Redesigning Occupational Therapy Cancer-related Fatigue Education at RBWH	Consultation	Not applicable
Michelle Cottrell	Perry Judd, Sue Laracy , Cate Carter (RDH), Jacqueline Nix (RDH), Leonie Naumann, Robyn Scheer, Jennifer Strong, Sonia Sam	Prospective surveillance and early intervention for lymphoedema (SAIL) in Breast Cancer patients: an evaluation of a standardised model of care in Metro North Hospital and Health Service.	Not applicable	0
Rhiannon Young	Helen MacLaughlin, Megan Crichton, Patsy Yates, Joanne Hiatt	Person-centred nutrition in palliative cancer care	Not applicable	Not applicable

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
Sarah Andersen	Andrea Henden, Heidi Staudacher (Deakin Uni), Jacinta Smith (Consumer), Midori Nakagaki, Nicole Gavin (Cancer Care)	Impact Leukaemia	Not applicable	Not applicable
Sarah Andersen	Andrea Henden, Heidi Staudacher (Deakin), Jacinta Smith (Consumer), Midori Nakagaki, Nicole Gavin (Cancer Care), Tamara Wolf	Impact BMT	Not applicable	Not applicable
Sarah Andersen	Teresa Brown , Glen Kennedy (Cancer Care), Frederik Steyn (Neurology & UQ), Rebecca Fichera	Energy expenditure in patients undergoing allogeneic stem cell transplantation	Not applicable	Not applicable
Sarah Andersen	Andrea Henden (QIMR), Glen Kennedy (Cancer Care), Merrilyn Banks	Prebiotics, the gastrointestinal microbiome and clinical outcomes post allogeneic stem cell transplantation	Not applicable	30
Sarah Andersen	Teresa Brown, Claire Blake, Rachel Willims, Helen MacLaughlin , Dannielle McCormack, (QUT), Christine Johnson (QUT)	Micronutrient requirements during graft versus host disease post allogeneic stem cell transplantation: a systematic review	Not applicable	Not applicable
Sarah Wilson	Clare Burns , Bena Brown (Metro South/UQ)	Development of clinical and videofluoroscopic assessment tools for the evaluation of dysphagia following laryngectomy: An e-Delphi process	Not applicable	Not applicable
Teresa Brown	Merrilyn Banks , Brett Hughes, Charles Lin, Liz Kenny (Cancer Care), Louise Campbell (Qld PET Service), Judy Bauer (Monash)	Assessment of sarcopenia and malnutrition in patients with head and neck cancer undergoing treatment of curative intent – implications for practice	Not applicable	0
Teresa Brown	Daniel Hwang (UQ), Elise Treleaven , Brett Hughes, Liz Kenny, Charles Lin, (Cancer Care) Penny Webb (QIMR), Anita Pelecanos (QIMR), Judy Bauer (Monash)	A feasibility study to investigate taste changes post treatment in patients with head and neck cancer and their association with genes and dietary behaviour	Involvement	0
Teresa Brown	Ryan Sommerville (ENT), Tom Slaughter (ENT), Clare Burns (Speech Pathology) , Brett Hughes (Cancer Care), Judy Bauer (Monash)	Nutrition and swallowing outcomes following TORS for head and neck cancer	Involvement	9
Teresa Brown	Ryan Sommerville (ENT), Abigail Walker (ENT), Stephanie Yau (ENT), Joanne Hiatt, Rebecca Fichera, Clare Burns (Speech Pathology) , Brett Hughes (Cancer Care), Judy Bauer (Monash)	Nutrition and swallowing outcomes following skull base surgery	Involvement	18
Teresa Brown	Belinda Camilleri , Brett Hughes (Cancer Care), Judy Bauer (Monash)	Nutrition outcomes following immunotherapy for head and neck cancer	Involvement	Not applicable

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
Teresa Brown	Elise Treleven, Claire Blake, Rebecca Fichera, Jo Hiatt , Omar Briek (Maxillofacial surgery), Ryan Sommerville (ENT), Milap Rughani (Plastics), Brett Hughes (Cancer Care), Judy Bauer (Monash)	Developing nutrition care pathways and prophylactic gastrostomy insertion for head and neck surgery	Consultation	Not applicable

Collaborative Research Activity Involving RBWH Department / Research Group

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
Anna Edwards (Toowoomba/UQ)	Teresa Brown , Brett Hughes (Cancer Care), Judy Bauer (Monash)	Regional H&N cancer centre nutrition care and experience	Involvement	14
Courtney Cross (University of Adelaide)	Rohit Joshi, Hannah Wardill, Joanne Bowen, Ryan O'Hare Doig, Sarah Andersen , Bronwyn Cambareri, Heidi Staudacher, Denelle Cosier, Angela Walls, Beverley Fosh, Ms Monique Bareham	The Adhere Study: Evaluating an accessible dietary fibre intervention to improve outcomes in people with breast cancer	Consultation	Not applicable
Judy Bauer (Monash)	Lauren Hanna (Monash), Teresa Brown , Merran Findlay (Uni of Sydney), Belinda Vangelov (Prince of Wales, Sydney)	Body composition and sarcopenia in head and neck cancer in a national dataset	Not applicable	Not applicable
Laurie Wennerholm (White Plains Hospital New York, UQ)	Clare Burns , Liz Ward (CFAHR/UQ),	Laryngectomy care pathways: Examining patient and clinician perspectives	Not applicable	Not applicable
Liz Ward (CFAHR/UQ)	Clare Burns , Laurie Wennerholm (White Plains Hospital New York, UQ)	Examining international laryngectomy care during the COVID-19 pandemic: Informing a consensus-driven pathway for speech language pathology management	Not applicable	Not applicable
Liz Ward (CFAHR/UQ),	Jasmine Jones (UQ), Clare Burns , Laurelie Wall (UQ), Rebecca Nund (UQ), Nicky Graham (QH) , Wendy Comben (THHHS), Emily Missenden (NWHHS))	Enhancing Speech Pathology Workforce and Service Capabilities to Deliver Services to Patients with Head and Neck Cancer	Not applicable	Not applicable

Research Publications

Authors

Investigator	ORCID ID
Ann-Louise Spurgin	https://orcid.org/0000-0001-7799-9703
Belinda Lehn	https://orcid.org/0000-0001-8635-941
Clare Burns	https://orcid.org/0000-0002-9752-1739
Elise Treleaven	https://orcid.org/0000-0002-6982-2593
Emilie Croisier	https://orcid.org/0000-0002-2304-6840
Joanne Hiatt	https://orcid.org/0000-0001-7019-6545
Kate Thompson	https://orcid.org/0000-0002-2269-1215
Kelsey Pateman	https://orcid.org/0000-0002-5230-1492
Laura Moroney	https://orcid.org/0000-0002-4320-907X
Michelle Cottrell	https://orcid.org/0000-0001-7300-1467
Sarah Andersen	https://orcid.org/0000-0002-9200-8186
Shana Taubert	https://orcid.org/0000-0002-1514-6833
Shaun O’Leary	https://orcid.org/0000-0002-2574-129X
Teresa Brown	https://orcid.org/0000-0002-5127-1631

Publications in 2025

Journal Articles (RBWH staff or consumers in bold)

Croisier E, Brown T, Grigg A, **Chan P**, Bauer J. Dietary counselling to increase soluble fibre in patients with gynaecological cancers undergoing pelvic radiotherapy: A feasibility study. Journal of Human Nutrition and Dietetics. 2024 Nov 25;38(1).

Hanna L, Nguo K, **Brown T**, Bauer J. Energy expenditure in head and neck cancer: a systematic review and meta-analysis. Supportive Care in Cancer. 2025 Dec 17;34(1).

Brown T, Cooney L, Smith D, Elvin-Walsh L, Kern E, **Ahern S**, et al. Comparison of Prophylactic Versus Reactive Tube Feeding Approaches on Weight Loss and Unplanned Hospital Admissions in Patients with Head and Neck Cancer Receiving Chemoradiotherapy. Current Oncology [Internet]. 2025 Dec 21 [cited 2026 Feb 26];33(1):5. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC12840307>

Wilson SE, Brown B, **Burns CL**. Clinical Swallow Examination Following Laryngectomy: An International e-Delphi Consensus Process. Dysphagia. 2025 Jan 21;

Hughes R, Corry J, Rischin D, Bressel M, Kenny L, **Lehn B**, et al. Swallowing and Communication Outcomes Post Chemoradiotherapy for Low-Risk Human Papillomavirus (HPV)-Associated Oropharyngeal Squamous Cell Carcinoma: A Substudy of TROG 12.01. Head & Neck. 2025 Jul 15;47(12):3310–20.

Hayes SC, Bernas M, Plinsinga ML, Pyke C, Saunders C, Piller N, et al. Breast cancer-related arm lymphoedema: a critical unmet need. eClinicalMedicine [Internet]. 2024 Sep [cited 2025 Apr 14];75:102762. Available from: [https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370\(24\)00341-9/fulltext](https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00341-9/fulltext)

Keynote or Plenary Lectures given in 2025

Date	Title
25/09/2025	Clare Burns. Plenary session - Telepractice in total laryngectomy. National Conference on Alaryngeal Speech and Swallowing, Mysore, India
13/11/2025	Maree Grier. Plenary session - Debunking misconceptions in psycho-oncology - Myths and misunderstandings. At 2025 Joint Meeting of the Clinical Oncology Society of Australia Annual Scientific Meeting and the International Psycho-Oncology Society Congress